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Resumo 
 
A degenerescência macular relacionada com a idade (DMRI) é a principal causa de 
cegueira na população idosa no mundo ocidental. Uma das principais características da 
DMRI é a formação de drusen, agregados de proteínas danificadas provocados por uma 
digestão incompleta dos segmentos externos dos fotorreceptores. Nas últimas décadas 
tem sido feito um grande esforço de forma a compreender os mecanismos que levam à 
formação dos drusen e o papel do epitélio pigmentado da retina (EPR) na sua formação; 
contudo, os processos que levam à formação dos drusen continuam desconhecidos.  
Os resultados obtidos anteriormente sugerem uma relação entre a autofagia e a via 
ubiquitin proteassoma (VUP). As vias proteolíticas estão interligadas, de modo a 
assegurar a homeostase celular, e parecem ter um papel importante no desenvolvimento 
da DMRI. Estudos indicam uma diminuição na VUP na DMRI, provavelmente induzida 
pelo stress oxidativo. Apesar da actividade autofágica basal das células diminuir com a 
idade, estudos recentes apontam para um aumento no fluxo autofágico nas células do 
EPR envelhecidas. A nossa hipótese é de que na DMRI proteínas danificadas não são 
degradadas pela VUP, sendo exocitadas e agregando-se, formando os drusen. Este 
trabalho pretende clarificar os mecanismos moleculares e principais agentes ligados à 
disfunção do EPR, bem como avaliar a relação entre a VUP e a autofagia na DMRI. 
Numa primeira abordagem, o proteassoma foi cronicamente inibido ao adicionar 
MG-132 a células ARPE-19, uma linha celular usada como modelo para o EPR humano. 
O tratamento com 0.20μM MG-132 durante 48h, apesar de não ter induzido 
citotoxicidade, levou à inibição do proteassoma, como concluído pela acumulação de 
conjugados de ubiquitina e diminuição da degradação da CDKN1A/p21, um substrato do 
proteassoma. 
O efeito da inibição do proteassoma na macroautofagia também foi investigado. 
Células do EPR incubadas com o inibidor do proteassoma apresentaram actividade 
autofágica aumentada, verificada pelo aumento nos níveis proteicos de LC3-II. Esta 
observação sugere uma autofagia induzida pelo MG-132, que foi confirmada pelo 
aumento do fluxo autofágico, avaliado pelos valores de LC3-II na presença e na ausência 
de BafA1, um inibidor de proteases lisossomais.  Além disso, os níveis protéicos de HIF-
1α também foram analisados, uma vez que o nosso grupo recentemente demonstrou que o 
HIF-1α pode ser degradado por autofagia mediada por chaperonas (AMC). Foram 
encontrados níveis proteicos de HIF-1α reduzidos nas células do EPR sob inibição 
proteasomal, mais uma prova de que MG-132 induz autofagia. Curiosamente, apesar de 
induzir acumulação da LC3-II, o MG-132 aumenta o substrato autofágico SQSTM1/p62 
nas células do EPR, como verificado por Western blotting e imunofluorescência. Os 
níveis proteicos de SQSTM1/p62 foram restaurados com a adição de CHX às células, 
indicando que o aumento de SQSTM1/p62 foi causado por estimulação da síntese 
proteica. A actividade lisossomal das células do EPR incubadas com MG-132 foi 
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investigada, através da medição dos níveis proteicos de CatD, a protéase lisossomal mais 
abundante. Após exposição a 0.20μM MG-132, os níveis de catD tanto nas formas 
percursoras como na madura estão aumentados, o que sugere um esforço da célula para 
formar catD activa e assim aumentar a actividade lisossomal. Estes dados indicam que a 
inibição do proteassoma com MG-132 estimula a autofagia nas células do EPR. 
Por imunocitoquímica, verificou-se que o MG-132 induz um aumento na 
imunoreactividade para proteínas ubiquitinadas, principalmente na zona nuclear/ 
perinuclear. Com MG-132, SQSTM1/p62 e proteínas ubiquitinadas apresentam uma co-
localização quase completa, o que sugere que a SQSTM1/p62 liga-se às proteínas 
ubiquitinadas, formando agressomas como descrito para várias doenças relacionadas com 
a idade. Com o proteassoma inibido SQSTM1/p62 actua como um adaptador para as 
proteínas ubiquitinadas, entregando-as aos lisossomas para degradação autofágica. 
Na DMRI, em simultâneo com inibição do proteassoma ocorre a activação da 
autofagia nas células do EPR. A autofagia foi estimulada por starvation ou por 
rapamicina, um inhibidor do mTOR. Através da LC3-II e da SQSTM1/p62, verificámos 
que 6h é o tempo ao qual a autophagy modelada pela starvation é máxima. Células do 
EPR tratadas com os activadores de autofagia apresentaram fluxo autofágico aumentado, 
uma vez que tanto a starvation como a rapamicina aumentaram a LC3-II e diminuíram a 
acumulação de SQSTM1/p62 induzida pela BafA1.  
De forma a estabelecer um modelo para a AMD, células ARPE-19 foram expostas 
simultaneamente a MG-132 e um dos activadores da autofagia. Starvation foi o indutor 
mais eficaz. Tratamento concomitante das células do EPR com MG-132 e starvation 
estimulou fortemente a autofagia. Os resultados sugerem que, apesar de ser um substrato 
autofágico, SQSTM1/p62 não é degradada quando o proteassoma está inibido, mesmo 
quando temos em paralelo autofagia estimulada.  
Em suma, nós propomos um modelo in vitro para a DMRI, em que a ligação entre as 
vias proteolíticas é analisada. Na DMRI, a diminuição da actividade proteolítica resulta 
na acumulação de proteínas poliubiquitinadas, em agressomas. A inibição do 
proteassoma induz autofagia, através da SQSTM1/p62, que entrega as proteínas 
poliubiquitinadas para degradação autofágica no lisossoma. Porém, com o tempo o 
lisossoma atinge a sua capacidade máxima e acaba por não degradar todas as proteínas 
danificadas. A nossa hipótese é de que o EPR envelhecido liberta as proteínas 
intracelulares via exossomas, o que contribui para a formação e acumulação dos drusen. 
Estudos futuros são necessários a fim de percebermos os mecanismos por detrás da 
libertação dos exossomas e acumulação dos drusen, em particular quando o proteassoma 
está inibido e a autofagia estimulada, como usado neste trabalho.   
 
Palavras-chave: Degenerescência macular relacionada com a idade, via 
ubiquitin proteassoma, autofagia, SQSTM1/p62.  
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Abstract 
Age-related macular degeneration (AMD) is the main cause of blindness in the 
western world in elderly population. One of the principal features of AMD is the 
formation of drusen, damaged protein aggregates caused by incomplete photoreceptor 
outer segments digestion. Over the past decades a significant effort has been made to 
understand the mechanisms underlying drusen biogenesis and the involvement of RPE in 
their formation; however, the processes that lead to drusens formation remain unknown.  
Accumulated evidence suggests a crosstalk between autophagy and the ubiquitin 
proteasome pathway (UPP). The proteolytic pathways are not compartmentalized, 
working together to ensure the cell homeostasis. Proteolytic pathways may have a key 
role in the development of AMD. The evidence clearly indicates an impairment of UPP in 
AMD, probably induced by oxidative stress. Although basal autophagic activity of living 
cells decreases with age, recent studies reported enhanced autophagy flux in aged RPE 
cells. We hypothesize that in AMD the misfolded/damaged proteins are not degraded by 
UPP, so they are exocytosed and aggregate, forming the drusen. This study aims to 
clarify the molecular mechanisms and key players intrinsically linked to RPE dysfunction 
and to evaluate the crosstalk between UPP and autophagy in AMD.  
As a first approach, chronic proteasome inhibition was performed by adding MG-132 
to ARPE-19 cells, a cell line commonly used as human RPE model.  Treatment with 
0.20μM MG-132 for 48h did not induce any significant cytotoxic effect and was able to 
successfully inhibit the proteasome, as conclude by accumulation of ubiquitin conjugates 
and impaired degradation of CDKN1A/p21, a known proteasome substrate. 
The effect of proteasomal impairment in macroautophagy was also investigated. We 
found enhanced autophagy activity in RPE cells incubated with the proteasome inhibitor, 
verified by the increase in LC3-II protein levels. This finding suggests an MG-132-
induced autophagy, which was confirmed by the enhanced autophagic flux, assessed by 
measuring LC3-II in the presence and absence of BafA1, a lysosomal protease inhibitor. 
Moreover, the HIF-1α protein levels were also analyzed, since recently our group shown 
that HIF-1α can be degraded by CMA. Accordingly, we found reduced HIF-1α protein 
levels in RPE cells due proteasomal inhibition, further evidence of MG-132-induced 
autophagy. Interestingly, although the MG-132 induced accumulation of LC3-II, we 
found that it significantly increased autophagy-specific substrate SQSTM1/p62 in RPE 
cells in a concentration-dependent manner, as verified by both Western blotting and 
immunofluorescence. SQSTM1/p62 protein levels were restored when CHX was added 
to the cells, indicating that this increase in SQSTM1/p62 protein content was caused by 
an enhanced protein synthesis. The lysosomal activity of RPE cells incubated with MG-
132 was also investigated, by measuring the protein levels of CatD, the most abundant 
lysosomal protease. We found increased levels of catD at both precursors and mature 
forms after exposure to 0.20μM of MG-132, suggesting an effort of the cell to enhance 
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active catD formation and thus improve lysosomal activity.  Taken together, this data 
strongly indicate that MG-132-induced proteasomal inhibition stimulates autophagy 
lysosomal pathway in RPE cells. 
By Immunocytochemistry, we observed that MG-132 induced an increased 
immunoreactivity for ubiquitinated proteins mainly in the nuclear/perinuclear 
compartment. With MG-132, SQSTM1/p62 and ubiquitinated proteins co-localize almost 
completely and the immunoreactive puncta were very intense, suggesting that 
SQSTM1/p62 binds to ubiquitinated proteins, constituting SQSTM1-ubiquitin 
aggresomes as described to several age-related diseases. Our data indicate that upon 
proteasomal inhibition SQSTM1/p62 acts as a cargo adaptor for ubiquitinated proteins, 
shuttling them to lysosomes for autophagocytic degradation.  
In AMD, in parallel with proteasome impairment occurs the activation of autophagy 
in RPE cells. Autophagy was stimulated by starvation or with rapamycin, an mTOR 
inhibitor. By LC3-II and SQSTM1/p62 protein levels, we verify that 6h was the time 
point in which RPE cells exhibits maximal serum starvation-triggered autophagy 
activation. RPE cells treated with autophagy activators exhibited an increase in the 
autophagic flux, as both starvation and rapamycin increased LC3-II protein content and 
decreased the BafA1-induced SQSTM1/p62 accumulation. 
In order to establish an accurate cell model of AMD, ARPE-19 cells were exposed 
simultaneously to both MG-132 and one of the tested autophagy inducers. Starvation was 
the most effective autophagy inducer. Concomitant treatment of RPE cells with MG-132 
and starvation strongly stimulated autophagy. Our data suggest that although 
SQSTM1/p62 is an autophagic substrate, this protein is not degraded upon proteasome 
inhibition, even when autophagy is stimulated. 
Overall, we proposed an in vitro model for AMD, in which the crosstalk between the 
two major proteolytic pathways was analyzed. In AMD, impairment of proteasomal 
activity results in accumulated polyubiquitinated proteins in SQSTM1/p62-ubiquitin 
aggresomes. Proteasomal inhibition induces autophagy activation, through the action of 
SQSTM1/p62, which triggers polyubiquitinated proteins to autophagy clearance in the 
lysosome. However, with time lysosome becomes overloaded and thus damaged proteins 
cannot be degraded. We hypothesize that aged RPE releases intracellular proteins via 
exosomes and, therefore, this event contributes to formation and accumulation of drusen 
in AMD. Further studies investigating the mechanisms underlying exosomes release and 
accumulation of drusen, in particular in conditions of proteasome inhibition and 
autophagy activation that were used in this work, should aim at clarifying this issue. 
 
Key words: Age-related macular degeneration, ubiquitin-proteasome pathway, 
autophagy, SQSTM1/p62 
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1. The human retina 
The ocular globe is constituted by six muscles involved in the ocular movements and 
three concentric layers working together to provide vision, nutrition and protection to the 
eye. 
The exterior layer is constituted by the cornea and sclera. The medium or vascular 
layer is formed by the iris, choroid, corium and uvea. The interior layer is composed by 
the retina (Figure 1.1) (Parier and Soubrane, 2008, Bhutto and Lutty, 2012).  
 
Figure 1.1 – The structure of human eye. From http://emeraldeye.com/images/illustrations/eye.jpg 
 
The retina is the component of the eye responsible for image formation. It converts 
the visual image to electric impulses which are sent to the brain via the optic nerve. The 
retinal supply and oxygenation are sparse compared with the rate of oxygen consumption. 
Phototransduction and neural signaling are energy-consuming processes. The anatomy of 
the human retina assure high transparency and photoreceptor density (Bhutto and Lutty, 
2012; Handa, 2012).  
The human retina is approximately 0.2 mm thick, and has an area of approximately 
1100 mm
2
. Each retina possesses about 200 million neurons. The only area of the retina 
that is “blind” as it lacks photoreceptors is the optic disc, where neuronal cells merge to 
form the optic nerve. Temporal to the optic disc is the macula, the central posterior 
portion of the retina. The macula has the highest concentration of photoreceptors, which 
facilitate central vision and provides high-resolution visual acuity (Chopdar, 
Chakravarthy and Verma, 2003; Jager, Mieler and Miller, 2008). It has about 1.5mm of 
diameter and is composed by two or more layers of ganglion cells. In the center of the 
macula lays the fovea, a depression with high concentration of cone cells, responsible for 
the central vision (Chopdar, Chakravarthy and Verma, 2003).  
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The whole retina is frequently described as having ten layers, constituted of three 
major types of cells: neurons, glial cells and blood vessels. The majority of these cell 
types are affected to some degree in many retinal diseases including age-related macular 
degeneration (AMD). Retina is primarily a neuronal tissue. The glial cells of the retina, 
Müller cells and astrocytes, serve as support cells for the neurons and blood vessels. 
Although its multilayered structure, the retina can be functionally divided in two 
parts: the neuronal retina, composed by the photoreceptors (cones and rods) and their 
neuronal connections, is responsible for the phototransduction process; the retinal 
pigment epithelium (RPE) and its basal lamina known as Bruch’s membrane (BrMb) 
maintain the integrity between retina and choroid (Figure 1.2) (Chopdar, Chakravarthy 
and Verma, 2003; Rattner and Nathans, 2006).  
 
Figure 1.2 – Schematic diagram of the retina and choroid, showing the retinal layers. The choroidal 
vasculature is at the top and the inner retina is at the bottom. The vasculature of the inner retina is shown on 
the lower right. Arrows indicate the local diffusion of oxygen, nutrients and waste products between 
choroidal vasculature and the outer retina. CH, choroid; GCL, ganglion cell layer; INL, inner nuclear layer; 
IPL, inner plexiform layer; ONL, outer nuclear layer; OPL, outer plexiform layer; OS, outer segments; 
RPE, retinal pigment epithelium. Adapted from Rattner and Nathans, 2006. 
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1.1.   Photoreceptor cells 
The photoreceptors are neurons located in posterior retina which are responsible of 
phototransduction, a process by which light is converted in electrical signals that 
stimulate the neural impulse transmission to the brain through alterations in the 
membrane potential.  
Histologically, the photoreceptors are classified into two types: cones and rods. The 
cones are present predominantly in the foveal region, whereas the rods are more common 
at the periphery of the retina. Rods are responsible for sensing motion, contrast and 
brightness, while cones are necessary for color vision, fine detail perception and spatial 
resolution. In humans there are three types of cones: red, green and blue cones, according 
with their response to different wavelengths (Bhutto and Lutty, 2012).  
The photoreceptor cells are the primary neurons in the visual pathway. They 
differentiate longitudinally into two major divisions that extend from their cell body: the 
inner and outer segments. The inner segment contains the metabolic apparatus, namely a 
high level of mitochondrias needed to produce energy, since photoreceptors are cells 
metabolically very active. Photoreceptors consume more oxygen per gram of tissue than 
any other cell of human body and their oxygen levels are approximately zero in the 
absence of light (Wangsa-Wirawan and Linsenmeier, 2003). In its turn, the outer 
segment’s major function is the conversion of light into neuroelectrical energy (Young, 
1967).  
In order to maintain the photoreceptor excitability, the outer segments are shed from 
the photoreceptors, allowing a constant renewal of photoreceptor outer segments (POS) 
(Young, 1967; Strauss, 2005; Bhutto and Lutty, 2012; Handa, 2012).  
 
 
1.2. The retinal pigment epithelium (RPE) 
The RPE is a monolayer of pigmented cells and forms part of the blood-retinal 
barrier (BRB) (Burke and Hjelmeland, 2005; Rattner and Nathans, 2006; Strauss, 2005). 
The apical membrane of the RPE faces the photoreceptor outer segments, whereas its 
basolateral membrane faces BrMb, a semi-permeable exchange barrier that separates the 
RPE from the choroid (Strauss, 2005). RPE cells receive their name from the melanin 
pigment granules (melanosomes) located in the apical cytoplasm (Burke and Hjelmeland, 
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2005). These pigments are responsible for absorbing the light focused by the lens in the 
retina (Rattner and Nathans, 2006; Handa, 2012; Strauss, 2005). 
In fact, together the RPE and photoreceptors form a functional unit. Mutations in 
genes that are expressed in the RPE, such as MerTK or RPE65, can lead to photoreceptor 
degeneration (Gu et al., 1997; Thompson et al., 2002). On the other hand, mutations in 
genes expressed in photoreceptors, such as ABCR, can lead to degenerations of the RPE 
(Strauss, 2005). 
In addition to supporting normal photoreceptor action, the RPE is essential for visual 
function. The RPE transports ions, water, and metabolic end products from the subretinal 
space to the blood and takes up nutrients such as glucose, retinol and fatty acids omega-3 
from the blood, providing to POS the nutrients required to maintain their function 
(Ambati and Fowler, 2012; Strauss, 2005).  
Another RPE function in the maintenance of photoreceptor excitability is the 
phagocytosis of shed photoreceptor outer segments (Strauss, 2005). Photoreceptors are 
exposed to intense levels of light. This leads to accumulation of photo-damaged proteins 
and lipids. To maintain the photoreceptor excitability, the POS undergo a constant 
renewal process. The POS are digested daily by the RPE and essential substances, such as 
retinal, are recycled and returned to photoreceptors to rebuild light-sensitive outer 
segments from the base of the photoreceptors (Bhutto and Lutty, 2012; Rattner and 
Nathans, 2006).  
The RPE also plays an important role in the visual cycle, by participating in the light-
dependent cycling and reisomerization of retinal (the vitamin A derivative that serves as 
the chromophore for the visual pigments). Photoreceptors are unable to reisomerize all- 
trans-retinal, formed after photon absorption, back into 11-cis-retinal. Thus retinal is 
transported to the RPE, reisomerized to 11-cisretinal and transported back to 
photoreceptors. This process is known as the visual cycle of retinal (Rattner and Nathans, 
2006; Strauss, 2005). 
In addition to these functions, the RPE is able to produce and to secrete a variety of 
growth factors, as fibroblastic (FGF-1, FGF-2 and FGF-5) and transforming growth 
factor beta (TGF-β) (Dunn et al., 1998; Matsumoto et al., 1994; Sternfeld et al., 1989; 
Tanihara et al., 1993 ; Bhutto and Lutty, 2012), as well as insulin-like growth factor I 
(IGF-I) (Martin, Yee and Feldman, 1992), vascular endothelial growth factor (VEGF) 
(Adamis et al., 1993), the pigmented epithelium derived factor (PEDF) (Streilein et al., 
2002) and some interleukins (Streilein et al., 2002; Bhutto and Lutty, 2012). 
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Altogether, RPE cells perform a variety of complex functions in the retina. 
Therefore, it is not surprising that deregulation of the RPE has a critical impact on retinal 
function and may lead to loss of visual function and blindness. 
 
 
1.3. Bruch’s membrane (BrMb) 
The BrMb is a thin connective tissue layer located between the RPE and the 
choriocapillaris. It is an elastin- and collagen-rich extracellular matrix with a penta-
laminar structure. The main components of BrMb are collagens type I, II, IV, V and VI, 
fibronectin and laminin (Bhutto and Lutty, 2012). 
BrMb principal role is to functions as a physical as well as biochemical barrier. It 
regulates the reciprocal diffusion of biomolecules, minerals, antioxidants and serum 
constituents between the choroid and the RPE (Bhutto and Lutty, 2012).  Moreover, this 
membrane provides physical support for RPE cell adhesion (Del Priore et al., 2002) and a 
surface for migration and differentiation of RPE cells (Gong et al., 2008), as well as a 
preponderant function in wound healing (Bhutto and Lutty, 2012; Tezel et al., 2004).   
The BrMb is unique to each human individual. Any alteration in the structure or 
composition of this membrane influences its diffusion properties and, ultimately, the 
function of the RPE and outer retina. Accumulating evidence suggests that the molecular, 
structural, and functional properties of BrMb are dependent on age, genetics, 
environmental factors, retinal location, and disease state (Bhutto and Lutty, 2012).  
 
 
1.4. Choriocapillaris (CC) 
Posterior to BrMB lies the choriocapillaris (CC), the capillary component of the 
choroidal vasculature. Whereas retinal vasculature supplies oxygen to the inner retina, the 
choroidal vasculature supplies oxygen to outer retina. The CC is composed by a single 
layer restricted to the inner portion of the choroid with feeding arterioles and draining 
venules entering the capillary plexus from below (Handa, 2012).  
CC provides nutrients to RPE cells, so they can be metabolically active. The 
nutrients are transported by the CC, diffuse through the BrMb and are delivered to the 
RPE. RPE cells then are responsible for transporting nutrients into the photoreceptors 
from the CC and also the removal of waste from the photoreceptors by either recycling it, 
completely degrading or exocytosing the remains for CC to remove from the retina. 
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Photoreceptors/RPE/BrMB/CC form an active complex, being each component directly 
dependent of the others and any alterations in one component will influence the whole 
complex (Figure 1.3) (Bhutto and Lutty, 2012; Rattner and Nathans, 2006).  
                   
 
Figure 1.3 – Schematic representation of the Photoreceptors/RPE/BrMB/CC complex. A human 
retinal transversal cross section showing the photoreceptors/RPE/BrMB/CC complex and the major cell 
types. A- CC; B- BrMb; C- RPE; D- Photoreceptors. Adapted from http://www2.ibb.unesp.br/Museu_Escola/ 
2_qualidade_vida_humana.html 
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2. Age-related macular degeneration  
Age-related macular degeneration (AMD) is the leading cause of blindness among 
older adults in industrialized countries and its prevalence is rising as a consequence of 
increasing longevity (Rattner and Nathans, 2006).  
Firstly described in 1885 by Otto Haab, this chronic disease is characterized by 
progressive changes that occur in the pigmented, neural and vascular layers of the 
macula, the central region of the retina bearing the highest concentration of 
photoreceptors. Accordingly, AMD can lead to severe impairment or loss of central 
vision (Ambati and Fowler, 2012).  
It is estimated that AMD affects 10 millions in United States (Friedman et al., 2004), 
and its prevalence increases drastically with age, rising  from 2% in people with 40 years 
old to 25% in people with the double of age (Friedman et al., 2004). More recently, a 
study from United Kingdom estimate that approximately 700 000 people will suffer from 
advanced AMD in 2020, which corresponds to 2.5% of the population with more than 50 
years old (Owen et al., 2012). The data also indicates that this pathology is more 
abundant in Caucasians and Asians, and more frequent in women than in men (Friedman 
et al., 2004; Owen et al., 2012).   
The earliest clinical manifestation and pathological feature of AMD is the formation 
of drusen, extracellular deposits of glycoproteins, lipids, and cellular debris located 
between Bruch’s membrane and the RPE (Ambati et al., 2003a; Rattner and Nathans, 
2006; Cook, Patel and Tufail, 2008). A few small drusens can be found in healthy 
individuals over the age of 50, but the presence of large or numerous drusen confers 
significant risk for AMD (Bhutto and Lutty, 2012; Klein et al., 1997).  
Clinically, AMD is divided into two subtypes: the atrophic AMD (“dry” form) and 
the exudative AMD (“wet” form) (Figure 1.4). Atrophic AMD is more common, 
affecting 85% to 90% of the patients. Generally this type is less severe, develops slowly 
and it can lead to partial blindness. Atrophic AMD manifests with drusen, geographic 
atrophy of RPE and photoreceptor dysfunction and degeneration. The patients have 
distorted vision, reading difficulties, limited vision at night or in conditions of reduced 
light.  
In this turn, exudative AMD is more debilitating and quickly leads to blindness if not 
treated (Guyer et al., 1986; Ambati and Fowler, 2012). It is very frequent AMD patients 
develop the atrophic form first and then the exudative, what makes that atrophic form is 
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considered as a risk factor or even a precursor of exudative form. The principal feature of 
exudative AMD is the choroid neovascularisation (CNV), the growth of new immature 
blood vessels from the choroid to the region underlying the RPE. The blood vessels may 
also extend through the RPE toward the subretinal space and retina. CNV can lead to 
blood and protein leakage in the subretinal space which, along with RPE atrophy and 
photoreceptor degeneration leads to vision loss (Ambati et al., 2003; Rattner and Nathans, 
2006; Cook, Patel and Tufail, 2008). 
 
 
Figure 1.4 – Fundus photographs in health and in AMD. (A) The ocular fundus of a healthy eye, 
showing normal pigmentation and retinal blood vessels. (B) The late-stage dry form of AMD, known as 
geographic atrophy with the characteristic large regions of depigmentation, especially in the macula (at the 
center of the image). (C) Wet AMD, where leaky blood vessels from the choroid invade the overlying 
retina. (Ambati and Fowler, 2012).  
 
As a multifactorial disease, the exact etiology and pathogenesis of the disease remain 
largely unclear (Ambati et al., 2003; Bhutto and Lutty, 2012; Handa, 2012). However, 
several risk factors have been identified. Besides age, some of these include smoking, 
light exposure, genetics, diet, obesity, hypertension and asteriosclerosis (Clemons et al., 
2005; Kaarniranta et al., 2013; Vingerling et al., 1995). The cigarette smoke is the factor 
which confers the major risk for AMD: smokers have about the triple of probability than 
the non-smokers to develop the disease (Chen et al., 2011; Wang et al., 2009). People 
who stopped smoking more than 20 years earlier were not at increased risk of AMD 
causing visual loss (Clemons et al., 2005; Thornton et al, 2005). 
A diet lacking antioxidants is also associated with an increased risk of AMD since 
the retina is the tissue with the bigger oxygen consumption level in human body. RPE 
cells are rapidly damaged when exposed to oxidants (Beatty et al., 2000; Liang and 
Godley, 2003) and therefore oxidative stress has been widely implicated in the 
development of AMD (Winkler et al., 1999; Handa, J.T., 2012).  
In the past decade, several genetic variants were associated to AMD, including 
variants in chromosome 1q32 (in CFH region) and 10q26 (LOC387715/ARMS2), as well 
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as in APOE and C2/BF genes (Yang et al., 2010). The link between genetics and AMD 
was reviewed by Swaroop and collaborators (Swaroop et al., 2007).  
Currently, there is not an established therapy to the early stages of AMD. 
Antioxidants are commonly recommended, although some studies had concluded that the 
use of antioxidants does not prevent the development of the disease (Evans, 2008). 
Although geographic atrophy remains without treatment, in cases where CNV is present 
photodynamic therapy with Verteporfin has been applied. VEGF was identified as a key 
mediator of CNV and in increased vascular permeability (Leung et al., 1989). Thus 
several inhibitors of VEGF have been used in AMD, being at this moment the more 
common treatment to prevent the disease progression (Wong et al., 2007).  
 
 
2.1.  The retina in age-related macular degeneration 
As mentioned before, AMD is characterized by visual function loss. The 
photoreceptors number diminishes a lot, and some studies indicate a bigger decrease in 
rods than in cones (Curcio et al., 2001). The photoreceptor degeneration seems to occur 
in the RPE/BrMB complex before the development of AMD (Curcio et al., 2001) and it is 
directly related to RPE degeneration, suggesting an important role of RPE in 
photoreceptors viability (Maeda et al., 1998; Bhutto and Lutty, 2012). 
In AMD, besides the drusen, it was verified the formation of laminar basal deposits 
located between the RPE and the BrMb, and also linear basal deposits within the BrMb 
(Bhutto and Lutty, 2012). These deposits are constituted by lipoproteins and other 
hydrophobic compounds resultant from incomplete degradation of photoreceptor 
metabolic end products and the debris of RPE metabolism. In addition, it was verified an 
increase in collagen fibers, resulting in a thicker BrMb. This affects the materials 
transport capacity of the membrane, which can contribute to AMD pathology (Bhutto and 
Lutty, 2012). 
With ageing, the RPE suffers several alterations, namely in the pigmentation and 
reduction of melanosomes. There is also an increase of lipofuscin levels and a decrease in 
RPE cell density (Delori et al., 2001), probably resultant from apoptosis caused by the 
accumulation of toxic substances (Figure 1.5). Lipofuscin is a mixture of non-degradable 
protein-lipid aggregates derived from the phagocytosis of POS (Sparrow and Boulton, 
2005). This generates reactive oxygen species (ROS) when exposed to light, which 
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increases RPE cells oxidative stress, contributing to the pathogenesis of AMD (Strauss, 
2005; Handa, 2012).  
 
 
Figure 5 - Schematic illustration of the RPE and BrMb histopathology associated with various 
macular degenerative processes. (a) normal retina and RPE; (b) the RPE with lipofuscin accumulation; 
(c) a drusen sandwiched between the RPE and BrMb; (d) a drusen with adjacent geographic RPE atrophy 
and loss of overlying photoreceptors; (e) choroidal neovascularization. OS, outer segments; IS, inner 
segments. Adapted from Rattner and Nathans, 2006. 
 
2.1.1. Oxidative stress and Age-related macular degeneration 
Oxidative stress, which refers to cellular injury caused by reactive oxygen species 
(ROS), has been proposed to play a causative or contributing role in a large number of 
diseases, such as heart disease, certain types of cancers, neurodegenerative disorders, 
cataract and AMD (Fernandes and Pereira, 2007; Olinski et al., 2007; Qin, 2007). In fact, 
a progressive increase of the oxidative cellular environment, due to the altered redox 
homeostasis, appears to be one of the hallmarks of the aging process. 
The retina is an ideal environment for the generation of ROS for several reasons. The 
oxygen consumption by the retina is much higher than any other tissue (Wangsa-
Wirawan and Linsenmeier, 2003). Moreover the phagocytosis and digestion of POS by 
RPE provides an additional burden since the shed outer segments are extremely rich in 
polyunsaturated fatty acids (PUFA), which can be readily oxidized, initiating a cytotoxic 
chain-reaction which produces ROS (Beatty et al., 2000; Liang and Godley, 2003).     
Consistent with a role of oxidative stress in the development of AMD, several studies 
indicate that exposure of RPE cells to oxidative stress results in an increase of angiogenic 
cytokines and growth factors, as well as in phenotypes associated with development of 
AMD (Kannan et al., 2006; Schlingemann, 2004; Zhou et al., 2005). 
In the last several years, it has been admitted that oxidative stress can be due to the 
accumulation of Advanced-Glycation End products (AGEs) in the RPE and Bruch’s 
membrane (Uchiki et al., 2011; Weikel et al., 2011). The drusen also contains AGEs 
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(Crabb et al., 2002). At this moment it is considered that AGEs may be involved in the 
development of choroid neovascularization in the wet AMD (Bhutto and Lutty, 2012).  
To combat these toxic ROS, the RPE contains a complex composition of various 
pigments that are specialized to absorb the different wavelengths, such as carotenoids 
lutein and zeaxanthin (Beatty et al., 2000). RPE is also rich in antioxidants, namely 
superoxide dismutase and catalase (Miceli et al., 1994). In addition, RPE cells contain 
glutathione and melanin, which itself can function as an antioxidant. The third line of 
defense is the cell’s physiological ability to repair damaged DNA, lipids and proteins 
(Strauss, 2005). However, with increasing age, the RPE antioxidant capability diminishes 
and thus aged RPE cells are more susceptible to oxidative damage (Liang and Godley, 
2003; Wang et al., 2009).  
 
 
2.1.2. Inflammation and Age-related macular degeneration 
Emerging evidence indicates a key role of inflammation in many age-related 
diseases, such as AMD (Fernandes and Pereira, 2007; McGeer, Klegeris and McGeer, 
2005; Donoso et al., 2006). Several studies have suggested a role for the complement 
system in AMD. The complement system is a central part of innate immunity, responsible 
of recognizing and eliminating invading microorganisms. Components of the 
complement pathway have been identified in drusen from eyes of patients with AMD 
(Mullins et al., 2000). Moreover, immune complexes and complement regulatory proteins 
are present in drusen and RPE (Crabb et al., 2002; Johnson et al., 2001; Nozaki et al., 
2006), which fits well with earlier observations of chronic inflammatory cells associated 
with atrophic RPE and with neovascular lesions (Ding, Patel and Chan, 2009; Hageman 
et al., 1999; Johnson et al., 2001). Taken together, these data strongly suggest that AMD 
pathogenesis has a chronic inflammatory component (Penfold et al., 2001; Rattner and 
Nathans, 2006). 
Interestingly, oxidative stress has been implicated in the inflammatory component of 
AMD (Zhou et al., 2006). The activation of redox-sensitive transcription factors may be 
involved in triggering the expression of pro-inflammatory cytokines, thus providing a 
link between oxidative stress and inflammation upon ageing (Chung et al., 2009; Handa, 
2012). Accordingly, previous studies carried out in our lab demonstrated that oxidative 
stress inactivates the proteasome in human retinal pigment epithelial cells (Fernandes et 
al., 2006) and this results in an overexpression of interleukin (IL)-8 (Fernandes et al., 
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2008). Moreover, the results from our group strongly indicate that increased IL-8 
production is regulated by several oxysterols, namely 25-OH (Catarino et al., 2012). 
Upon proteasome inhibition, this increase in IL-8 levels in RPE cells occurs by a 
mechanism involving p38 Mitogen-activated Protein Kinase (MAPK) and 
Phosphatidylinositol 3-kinase (PI3K) activation (Fernandes, 2009).  
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3. Proteolytic pathways 
As mentioned above, the RPE has been recognized as a primary site of pathology in 
AMD (Ambati, 2003; deJong, 2006). In AMD the RPE is not able to phagocytize the 
POS and scavenge the photoreceptors debris, which in healthy individuals occurs through 
proteolytic pathways (Young, 1967).  
Proteins are degraded via two main pathways in eukaryotic cells. Short-lived proteins 
are degraded by the proteasome, whereas long-lived proteins are degraded by autophagy. 
Protein aggregates that form during oxidative stress and other conditions, leading to 
misfolding and aggregation of proteins are degraded by autophagy (Ravikumar et al., 
2002, 2004). 
 
 
3.1. Ubiquitin Proteasome Pathway (UPP) 
The ubiquitin proteasome pathway (UPP) is the major proteolytic pathway within 
cells (Ciechanover, 2003). It is present in every eukaryotic cells, where it regulates vital 
biological processes, including cell division, differentiation, signal transduction, 
apoptosis, quality control and protein trafficking (Glickman and Ciechanover, 2002; 
Ciechanover, 2003; Shang and Taylor, 2004). This ATP-dependent pathway is also 
involved in the regulation of immune response and inflammation (Kloetzel, 2004; 
Qureshi et al., 2005). 
Degradation of a protein by the UPP requires two separate and sucessive steps: first, 
the substrate is tagged by covalent attachment of multiple ubiquitin molecules. Ubiquitin 
is a small peptide of 76 amino acids, which is highly conserved from yeast to humans, 
being the most highly conserved protein identified in eukaryotes (Ozkaynak et al., 1984). 
In a second stage, the polyubiquitinated protein is degraded by the 26S proteasome 
complex with the release of free ubiquitin that can be used in subsequent ubiquitination 
cycles (Glickman and Ciechanover, 2002; Shang and Taylor, 2012).  
The first step of UPP degradation, ubiquitin conjugation or ubiquitination, is a highly 
ordered process and involves three different classes of enzymes (Figure 1.6). Initially, an 
ubiquitin-activating enzyme (E1) activates ubiquitin in an ATP-dependent reaction to 
generate a high-energy thiol ester intermediate (Fig. 1.6 step 1). Then, ubiquitin is 
transferred to one of a number of ubiquitin-conjugating enzymes (E2) also via formation 
of a thiol-ester bond (Fig. 1.6 step 2). In the last step the activated ubiquitin is transferred 
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from the E2 enzyme to the substrate (Fig. 1.6 step 3), which can be either directly or 
through one member of the large family of ubiquitin protein ligases (E3). The ubiquitin 
molecule is normally transferred to an –NH2 group of an internal lysine in the substrate, 
though in a few cases ubiquitin can also be conjugated to the NH2-terminal amino group 
of the substrate (Fernandes, Ramalho & Pereira, 2006; Fernandes et al., 2008; Zhang et 
al., 2008). This sequence of reactions is repeated until a chain of at least four ubiquitin 
moieties is covalently attached to the substrate (Fig. 1.6 step 4), which is required for 
substrate recognition by a large protease complex called the proteasome (Fig. 1.6 step 5) 
(Fernandes and Pereira, 2007; Glickman and Ciechanover, 2002).   
 
Figure 1.6 - The ubiquitin–proteasome pathway (UPP). A cascade of enzymatic reactions leads to 
ubiquitination of lysine residues of the substrate. Adaptad from Lodish, Molecular Cell Biology 5th Ed. 
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The most common and best characterized fate of a poly-ubiquitinated protein is its 
translocation to a large proteolytic complex, the 26S proteasome, where it is degraded. 
However, sometimes only one ubiquitin is attached to the target protein in one or more 
amino acid residues, which results in the production of a mono-ubiquitinated protein. 
Proteins can be mono-ubiquitinated in different residues resulting in the formation of a 
multi-mono-ubiquitinated protein (Hicke and Dunn, 2003; Haglund and Dikic, 2005). In 
most cases the final destination of such proteins is not degradation but rather targeting to 
specific subcellular compartments, including the endocytic pathway (Haglund and Dikic, 
2005). 
The proteasome is a 2.5 MDa complex that functions primarily to degrade proteins 
that have been ubiquitinated. It works through a multi-step process in which ubiquitinated 
substrates are first recognized by the proteasome complex, followed by substrate 
unfolding, translocation into the catalytic pore and deubiquitination, finally ending with 
the cleavage of peptide bonds. The proteasome exists in various forms, the most 
commonly described being the 26S proteasome (Figure 1.7). 
The 26S proteasome complex consists of a 20S catalytic core or core particle (CP) 
and a regulatory particle (RP) consisting of two regulatory 19S caps (Ciechanover, 2003). 
The 20S particle is comprised of four heptameric rings arranged coaxially. The subunits 
of the 20S core are classified into α and β, with the noncatalytic α-heptameric rings 
forming each of the two outer rings and the catalytic β- heptamers forming the two inner 
rings (Bulteau et al., 2001; Ethen et al., 2007). The β-subunits contain three pairs of 
active sites that perform distinct proteolytic activities. The active sites have been 
classified as caspase-like, trypsin-like and chymotrypsin-like for cleavage of acid, basic 
and hydrophobic amino acids, respectively (Bulteau et al., 2001; Ethen et al., 2007). The 
19S caps are responsible for the recognition of ubiquitinated substrates and subsequent 
remove of the ubiquitin moieties from those substrates. The protein subunits present in 
the 19S cap also play an important role in unfolding the protein substrate and feeding it 
through the proteolytic chamber of the 20S core (Fernandes et al., 2006).  
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Figure 1.7 – Degradation of ubiquitinated substrates by the proteasome. The 26S proteasome first 
recognizes the polyubiquitin chain attached to the substrate. The substrate is unfolded and then translocated 
into the catalytic pore, in an ATP-dependent process. Once a substrate is committed to degradation, it is 
deubiquitinated, with the release of a free polyubiquitin chain. The substrate is then broken down into 
smaller peptides that subsequently exit the proteasome. RP, regulatory particle; CP, core particle. (Image 
taken from http://info.agscientific.com/advancing-biochemical-research/).  
 
The proper function of the UPS allows degradation not only of structural and 
constitutive proteins, but also of many regulatory proteins, including those which control 
biosynthetic pathways and cell cycle as well as transcription factors, proteins encoded by 
oncogenes and immune response proteins. It was, therefore, a matter of time to design 
and synthesize different groups of chemicals for proteasome inhibition with a potential 
use in the treatment of cancer and autoimmune and inflammatory diseases (Wojcik, 
2013).  
A wide variety of both natural and synthetic substances, which inhibit the activity of 
the proteasome by reversible or irreversible binding to the active site of its 20S catalytic 
subunit has been discovered (Wu et al., 2010). Of special clinical significance was the 
introduction into the cancer treatment the dipeptide boronic acid, bortezomib (PS-341), 
which reversibly and selectively inhibits the proteasome (Kawaguchi et al., 2011; Teicher 
et al., 1999; Zhang et al., 2014). MG-132 (carbobenzoxy-Leu-Leu-leucinal), a peptide 
aldehyde that reversibly inhibits proteasomal chymotrypsin- and caspase-like activities is 
widely used in experimental studies (Ciechanover, 1994; Lee & Goldberg, 1998; 
Fernandes et al., 2006).  
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The majority of intracellular proteins are degraded by the UPP. When the proteasome 
is inhibited, the damaged and misfolded proteins that were marked with ubiquitin for 
proteasomal degradation cannot be degraded. Instead, they accumulate as ubiquitinated 
protein conjugates (Ciechanover, 1994). Nowadays it is admitted that ubiquitin 
conjugates can be stored within the cell or degraded in lysosome by autophagy to avoid 
cytotoxicity (Bhutto & Lutty, 2012; Wang et al., 2009a) ; however the fate of ubiquitin 
conjugates is still unclear (Wojcik, 2013).  
 
3.1.1. CDKN1A/p21 
 
Several proteins have been considered as proteasome substrates since they are 
specifically degraded by the UPP, such as the cyclin-dependent kinase inhibitor 1A 
(CDKN1A) (Ferreira et al., 2013; Naujokat et al., 2000).  
Also known as p21/WAF1 and CDK-interacting protein 1 (CIP1), CDKN1A/p21 is a 
potent cyclin-dependent kinase (CDK) inhibitor, and thus functions as a regulator of cell 
cycle progression. CDKN1A/p21 expression is tightly controlled by the tumor suppressor 
protein p53. Activated p53 binds DNA and activates expression of several genes, 
including the CDKN1A gene. CDKN1A/p21 mediates growth arrest especially at G1 and 
S phase, by binding to and inhibiting the activity of several CDKs. When CDKN1A/p21 
is complexed with a CDK, the cell cannot continue to the next stage of cell division. This 
pathway is extremely important, namely considering the p53 function as a tumor 
suppressor, preventing cancer. CDKN1A/p21 plays also a role as a senescent cell-derived 
inhibitor (Gartel & Radhakrishnan, 2005).  
The exact mechanism by which CDKN1A/p21 suffers proteasomal degradation is 
not established yet. CDKN1A/p21, as well as several other cell cycle proteins, is 
ubiquitinated and its degradation is dependent upon the proteasome in vivo (King et al., 
1996; Koepp et al., 1999). Pharmacologic inhibition of the proteasome has been shown to 
increase the half-life of CDKN1A/p21 from less than 30min to more than 2h and results 
in the accumulation of CDKN1A/p21–ubiquitin conjugates (Sheaff, Singer, & Swanger, 
2000). The data indicates that CDKN1A/p21 turnover regulated by the proteasome does 
not require direct  ubiquitination (Sheaff et al., 2000).  CDKN1A/p21 is ubiquitinated at 
the N Terminus in vivo, which is sufficient for proteasomal breakdown. The degradation 
rate is dependent on the position of the ubiquitin chain (Bloom et al., 2003).  
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3.2.  Autophagy  
Autophagy, or autophagocytosis, is a ubiquitous and evolutionarily highly conserved 
group of mechanisms by which a healthy cell degrades misfolded and long-lived proteins, 
macromolecules and damaged or old organelles through the use of lysosomes (Marino et 
al., 2010). First described by Arstila e Trump (Arstila and Trump, 1969), autophagy is a 
key process in maintenance of cellular homeostasis, and thus it can be stimulated to cope 
with excessive organelle damage, aggregate removal and pathogen defense (Cuervo, 
2008).  
In mammalian cells three main types of autophagy have been described: 
microautophagy, chaperone-mediated autophagy (CMA) and macroautophagy (Peracchio 
et al., 2012) (Figure 1.8). All three forms of autophagy occur in the cell to assure its 
homeostasis. Nutrient deprivation, hypoxia, endoplasmic reticulum stress, proteasome 
malfunction or damage caused by drugs or radiation can decrease autophagy (Benbrook 
and Long, 2012). 
 
Figure 1.8 – Mechanisms of damaged proteins and organelles by mammalian cells. To maintain its 
homeostasis, the cells undergo several processes: autophagy (microautophagy, CMA and macroautophagy), 
heterophagy and the ubiquitin proteasome system (UPS) are represented. (Image taken from 
https://www.mdc-berlin.de/research_teams/proteomics_and_molecular_mechanisms_of_ neurodegenerative_diseases) 
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Microautophagy is a process in which defective molecules or organelles are directly 
engulfed into the lysosomes for degradation and recycling of their components (Li, Li & 
Bao, 2012).  
CMA refers to the chaperone-dependent selection of soluble cytosolic proteins that 
are targeted to lysosomes and then directly translocated across the lysosome membrane 
for degradation. In this proteolytic pathway, substrates containing a targeting motif 
biochemically related to the pentapeptide KFERQ are recognized by HSPA8/HSC70 
(heat shock 70 kDa protein 8) and selectively degraded in the lysosome. At the lysosomal 
membrane, the substrates interact with LAMP2A (lysosomal-associated membrane 
protein 2A) which acts as a CMA receptor, mediating the translocation of the substrate to 
the lumen of the lysosome (Cuervo and Dice, 1996; Ferreira et al., 2013).  
Macroautophagy (referred here as autophagy, a focus of this work), is a process in 
which a non-selective sequestration of cytoplasmic material is followed by digestion in 
lysosomes (Wojcik, 2013), and is the most used for the removal of large aggregates, 
including organelles (Mitter et al, 2012). Autophagy process begins with the formation of 
pre-autophagosomal structures (PAS) consisting of isolation membranes. These latter 
then become elongated and surround portions of cytoplasm containing oligomeric protein 
complexes and organelles to form a double-membraned vesicles called autophagosomes. 
The autophagosomes eventually fuse with lysosomes to form autolysosomes where the 
contents are digested and their components released for recycling within the cells 
(Benbrook and Long, 2012; Eskelinen and Safting, 2009; Patel et al., 2012). More 
specifically, the production and processing of autophagic vesicles is divided into 4 steps: 
1) initiation, 2) nucleation, 3) maturation and 4) fusion with lysosomes (Figure 1.9). 
These processes are mediated by a series of proteins encoded by autophagy-related genes 
(ATGs), which were originally characterized in yeast, and are highly conserved in higher 
eukaryotes (Klionskly et al., 2003).  
 
Figure 1.9 – Macroautophagy: a four-step process. Simplified illustration of macroautophagy, showing 
the protein complexes involved (Benbrook and Long, 2012). 
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During initiation, de novo synthesis of isolation membranes recruits lipids from 
several organelles depending on the cell type and stimulus. The endoplasmic reticulum 
appears to be the source of membrane lipids for the de novo formation of 
autophagosomes in the cytoplasm (Hayashi-Nishino et al., 2009). The mitochondrial 
enzyme, PS (phosphatidylserine) decarboxylase, converts PS to PE 
(phosphatidylethanolamine), which is needed for autophagosome formation. The 
complex of proteins that mediate initiation consists of ULK1 (uncoordinated 51-like 
kinase 1)/Atg1, Atg13 and Atg17/FIP200 (focal adhesion kinase interacting protein of 
200 kD).  
Nucleation is controlled by a PI3K called Vps34 (vacuolar protein sorting 34) that 
forms a complex with Beclin 1/Atg6 (Lindmo and Stenmark, 2006). Production of PIP3 
(phosphatidylinositol 3,4,5-trisphosphate) by Vps34 recruits Atg18 proteins to the 
isolation membrane allowing recruitment of LC3 (light chain of the microtubule- 
associated protein 1/ Atg8) (Polson et al., 2010).  
Two interdependent ubiquitin-like conjugation systems mediate the maturation of the 
autophagosome. In one system, LC3 is first cleaved by the Atg4 serine protease and then 
conjugated to PE by the Atg7 and Atg3 enzymes (Ichimura et al., 2000). The unmodified 
and lipidated forms of LC3 are termed LC3-I and LC3-II, respectively, and can be 
distinguished by Western blot analysis, a well accepted method to monitor autophagy 
(Klionsky et al., 2012; Mizushima & Yoshimori, 2007; Wang et al., 2009). The second 
system recruits LC3-II to the isolation membrane by the ubiquitin-like activity of Atg12, 
which is covalently bound to Atg5 and physically associated with Atg-16L to form a 
complex (Mizushima et al., 2001). Once the isolation membrane is formed, the Atg-12-5-
16L complex is released, which affords its utilization as a marker of isolation membrane 
formation (Mizushima et al., 2001). On the other hand, LC3-II remains associated with 
the autophagosome until fusion with the lysosome.  Thus the transition of diffuse to 
punctuate pattern of a transfected LC3-green fluorescent protein (GFP) fusion protein in 
the cytoplasm is a commonly used marker of autophagosome formation (Klionsky et al., 
2012; Tasdemir et al., 2008). 
Finally, the fusion step is mediated by dynein transportation of the autophagosomes 
along microtubules to fuse with lysosomes (Ravikumar et al., 2010). Inhibition of 
lysosomal acidification by Bafilomycin A1, a specific V-ATPase (vacuolar H+ ATPase) 
inhibitor, or by other lysosomal function inhibitors, CQ (Chloroquine) and HCQ 
(hydroxychloroquine), also cause accumulation of autophagosomes and is therefore used 
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to assess autophagic flux (Klionsky & Abdalla, 2012; Klionsky & Elazar, 2008; 
Mizushima & Yoshimori, 2007; Yamamoto et al., 1998). 
 
3.2.1. mTOR pathway  
Starvation, Hypoxia, depletion on ATP, necessary nutrients or growth factors and 
increased levels of misfolded /unfolded cytoplasmic proteins can induce autophagy 
(Wojcik, 2013).  The cascade of events linking the variety of autophagy-triggering 
signals with activation of downstream targets has not been completely elucidated. 
However, it is known that this process is strongly dependent on mTOR (mammalian 
target of rapamycin) pathway. 
In eukaryotic cells, mTOR is present in the form of at least two distinct multiprotein 
complexes of different intracellular activity and regulatory capacity. mTOR complex 1 
(mTORC1) is responsible for autophagy induction in response to stress, reduced insulin 
and IGF-1 signaling, and starvation (Jung et al., 2010). During such unfavorable 
conditions, mTORC1 dissociates from the ULK1 complex allowing it to initiate 
autophagosome formation. Low glucose levels or high levels of AMP (adenosine 5’-
monophosphate), which indicate low cellular energy status or stress, activate AMPK 
(AMP-activated protein kinase), which inhibits mTORC1 and stimulates autophagy 
(Jacinto et al., 2004; Wojcik, 2013).  
mTOR complex 2 (mTORC2) is a negative regulator of autophagy under conditions 
of nutrient depletion (Zhao et al., 2007). mTORC2 regulates Akt/PKB (protein kinase B) 
pathway, since it phosphorylates the serine/threonine protein kinase Akt/PKB at serine 
residues, which stimulates Akt phosphorylation by 3-phosphoinositide dependent protein 
kinase-1 (PDPK1)  and leads to full Akt activation (Sarbassov et al., 2005). mTORC2 
may also play a role in cancer, given its regulation of the widely studied oncogenetic Akt 
pathway (Guertin et al., 2009).  
Chemical inhibitors of mTORC1 currently in clinical use or in clinical trials, 
including rapamycin and analogs, induce autophagy and are often used as tools to study 
autophagy (Huang, Bjornsti, & Houghton, 2003; Li et al., 2013; Sahani, Itakura, & 
Mizushima, 2014). Rapamycin inhibits mTOR by associating with its intracellular 
receptor FKBP12 (FK-binding protein 12).  The FKBP12-rapamycin complex binds 
directly to the FKBP12-Rapamycin Binding (FRB) domain of mTORC1, inhibiting its 
activity (Huang, Bjornsti, & Houghton, 2003; Kamada et al., 2000).  
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3.3. Exosomes 
 
Another process of cell degradation involves exosomes.  Exosomes are 40–100 nm 
membrane vesicles of endocytic origin. Exosome biogenesis occurs within multivesicular 
bodies (MVBs) in the endosomal system (Bhat and Gangalum, 2011; Ohno, 2012). The 
endosomal system consists of primary endocytic vesicles, early endosomes, and MVBs. 
Early endosomes are located near the cell membrane where they act as the first port of 
call for primary endocytosed vesicles which are either recycled to the plasma membrane 
or targeted to MVBs. Proteins that are sequestered to the limiting membrane of MVBs 
can be selectively incorporated into intraluminal vesicles (ILVs) by invagination of the 
MVB membrane. From here, proteins are either degraded by fusion of the MVB with the 
lysosomal membrane and release of the ILV’s into the lysosome, or alternatively, they 
can be released into the extracellular environment as exosomes when MVBs fuse with the 
plasma membrane (Figure 1.10) (Bhat and Gangalum, 2011). Protein sorting and 
packaging into ILVs occurs in a regulated manner, involving a variety of mechanisms 
including mono-ubiquitination and the ESCRT (endosomal sorting complex required for 
transport) machinery (Hicke, 2001; Katzmann et al., 2002).  
 
 
Figure 1.10 - Exosome biogenesis occurs within MVBs of the endosomal system. Following 
endocytosis into early endosomes (EE), the cargo is packaged into ILVs within MVBs upon inward 
budding of the membrane. MVBs can then fuse with lysosomes resulting in degradation of the cargo, or 
alternatively, the MVBs can fuse with the plasma membrane, resulting in release of the ILVs as exosomes, 
a process which is regulated by Rab GTPases (Bellingham et al., 2012). 
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Exosomes from different cellular origins contain a common set of molecules: 
membrane and intracellular proteins, RNA, DNA, and microRNAs (Conde-Vancells et 
al., 2008; Mathivanan et al., 2010), which are essential for their biogenesis, structure and 
trafficking, as well as cell type-specific components (Biasutto et al., 2013).  
They have been reported in many biological fluids in vivo, including blood, urine, 
saliva, amniotic fluid, malignant ascites, pleural effusion, bronchoalveolar lavage fluid, 
synovial fluid, and breast milk (Admyre et al., 2007; Conde-Vancells et al., 2008). Many 
cells release exosomes into culture medium in vitro (Biasutto et al., 2013).  The reported 
functions of exosomes include the regulation of programmed cell death, angiogenesis, 
inflammation, coagulation, and the interaction between tumor cells and their environment 
(Conde-Vancells et al., 2008). Nowadays an increasing ongoing investigation focuses in 
the potential diagnostic and therapeutic applications of exosomes (Conde-Vancells et al., 
2008; Kang et al., 2014).  
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4. Proteolytic pathways in age-related macular degeneration  
4.1. UPP impairment in AMD 
 
Dysfunction of the UPP has been implicated in several age-related diseases, such as 
Alzheimer’s disease (Hope et al., 2003, Ihara et al., 2012), Parkinson’s disease (Dawson 
and Dawson, 2003), diabetic retinopathy (Fernandes et al., 2006) and cataract (Dudek et 
al., 2005; Shang et al., 2001). Consistent with an age-related decline in proteasome 
activity in many other tissues, a decline in proteasome activity upon ageing also was 
reported in the neural retina (Louie et al., 2002; Kapphahn et al., 2007).  
Impairment of the UPP may contribute to accumulation and aggregation of various 
forms of damaged proteins, such as those observed in subretinal deposits. Accumulation 
of ubiquitin or ubiquitin conjugates is prominent in age-related sub-RPE deposits, i.e. 
drusen, basal laminar deposits and inclusion bodies in human retinas (Naash et al., 1991, 
1997; Mauger et al., 1999), as well as in ganglion cells in rats with chloroquine 
retinopathy (Yoshida et al., 1997). The presence of ubiquitin in drusen raises the 
possibility that certain proteins become ubiquitinated within RPE but due UPP 
impairment its degradation does not occur and then ubiquitinated proteins are expelled 
from the RPE through exocytosis (Crabb et al., 2002; Leger et al., 2011).  
As previously referred, oxidative stress, including photo-oxidation, is often 
associated with accumulation of ubiquitinated proteins, both in neural retina and RPE 
(Fernandes et al., 2008, 2009; Zhang et al., 2008). Impairment of the UPP in RPE not 
only resulted in accumulation of oxidatively modified proteins (Zhang et al., 2008), but 
also increased the expression and secretion of pro-angiogenesis and pro-inflammation 
factors (Fernandes et al., 2006, 2008, 2009). 
 Inflammation has also a role in the development of AMD. Studies conducted in our 
lab shown that prolonged inhibition of the UPP in RPE triggers the expression of IL-8, a 
potent pro-inflammation and pro-agiogenesis factor (Fernandes et al., 2008, 2009). 
Disruption or up-regulation of NF-ĸB, p38 MAP kinase or PI3K signaling pathways also 
appears to be involved in the increased expression of IL-8 upon inhibition of the UPP 
(Fernandes et al., 2008, 2009). The inhibition of NF-ĸB signaling by proteasome 
inhibition is also related to the down-regulation of monocyte chemotactic protein 1 
(MCP-1) (Fernandes et al., 2006; Uetama et al., 2003). MCP-1 deficiency in mice causes 
AMD-like lesions, such as accumulation of lipofuscin in RPE, photoreceptor atrophy and 
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CNV (Ambati et al., 2003). Thus, down-regulation of MCP-1 expression upon 
proteasome inhibition may be a factor for AMD pathogenesis. 
Despite these data, direct evidence for UPP impairment in AMD pathogenesis is still 
lacking. Ethen et al. compared proteasome activity in retina from donor eyes with 
different grades of AMD and found that the chymotrypsin-like activity of the proteasome 
increased in neurosensory retina with disease progression (Ethen et al., 2007).  
Taken together, these data imply that age-or stress-related impairment of the UPP 
may contribute to pathogenesis of AMD via multiple UPP-requiring mechanisms (Shang 
and Taylor, 2012).  
 
 
4.2. Autophagy enhancement in AMD 
In RPE cells, simultaneously with proteasome inactivation, it has been admitted that 
occurs the activation of autophagy when in conditions of AMD (Mitter et al., 2012; Wang 
et al., 2009a and 2009b). Autophagy proteins are strongly expressed in the RPE (Wang et 
al. 2009a; Krohne et al. 2010; Viiri et al. 2010). Oxidative stress, hypoxia, the unfolded 
protein response and inflammation can active autophagy and are presented in AMD 
pathology (Kaarniranta et al., 2013).  
Many of the important pathogenic features of the RPE in AMD, e.g. lipofuscin 
accumulation, susceptibility to oxidative stress, mitochondrial damage and lysosomal 
dysregulation have an association with autophagy. However, it remains to be determined 
whether changes in autophagy flux are a cause or consequence of disease and whether 
autophagy changes reflect alterations in the formation or elimination of autophagosomes.  
Autophagy has been reported in photoreceptor cells (Reme and Young, 1977), and is 
associated with lipofuscin accumulation in rod and cone photoreceptors (Iwasaki and 
Inomata 1988). Autophagic proteins Atg9 and LC3 were found at high levels in the 
ganglion cell layer, a subpopulation of cells in the inner nuclear layer, the outer nuclear 
layer, and the RPE in normal mouse retina (Mitter et al., 2012). Under oxidative stress, a 
variety of retinal cells undergo autophagic cell death (Kunchithapautham and Rohrer, 
2007). 
Accordingly with autophagy enhancement in AMD, Wang and collaborators found 
increased levels of mitochondrial damage in RPE cells and ex vivo AMD donor eyes 
(Wang et al., 2009a). They also verified an enhanced autophagy and exocytic activity in 
aged RPE cells, as well as the presence of autophagic and exosome markers (CD63, 
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CD81 and LAMP2) in drusen in AMD donor eyes (Wang et al., 2009a and 2009b). In 
this last study several exosome markers (CD63, CD81 e LAMP2) were found between 
the RPE and the choroid of mice chronically exposed to cigarette smoke, contrary to 
controls (Wang et al., 2009b). Exosome protein markers appears to be located in BrMb, 
namely at choroid side (Wang et al., 2009b).  The high levels of exosomes make sense, 
since RPE is responsible for damaged macromolecules removal, whose levels are 
increased due toxic components from tobacco (Wang et al., 2009). It is admitted that 
increased autophagy can lead to the release of intracellular proteins via exosomes by the 
aged RPE, which may contribute to the formation of drusen. 
 
 
4.3. HIF-1α plays a role in AMD 
Hypoxia-Inducible Factor 1 (HIF1) is the most conserved hypoxia-inducible 
transcriptional complex (Salceda & Caro, 1997). HIF1 is a heterodimer composed of two 
subunits: hypoxia inducible factor 1, α subunit (basic helix-loop-helix transcription 
factor) (HIF-1α) and aryl hydrocarbon receptor nuclear translocator (ARNT/HIF-1β) 
(Arjamaa et al., 2009).  
The HIF signalling cascade controls vasculature adaptations to hypoxia (namely the 
formation of new blood vessels) and is also a key regulator of many other processes, 
including transcription of pro-angiogenic factors, such as VEGF, TGF-β3, and various 
components of glucose transport and glycolysis (Arjamaa, 2009; Shang & Taylor, 
2012;Lőw et al., 2013).  
In oxygen normal conditions (normoxia), HIF-1α is hydroxylated by specific prolyl 
hydroxylases. Once hydroxylated, HIF-1α is recognized by the von Hippel-Lindau tumor 
suppressor (VHL) protein (Maxwell et al., 1999), which acts as an ubiquitin ligase 
complex that targets HIF-1α for polyubiquitination and subsequent degradation by the 
proteasomal pathway (Bento et al., 2010; Cockman et al., 2000; Kamura et al., 2000). 
Decreased levels of oxygen lead to stabilization of HIF-1α (its hydroxylation is inhibited) 
and thus preventing ubiquitination, and consequent degradation. HIF-1α is then 
translocated into the nucleus, where it dimerizes with ARNT.  
Currently, a regulatory role of HIF-1α in the pathogenesis of AMD has been 
discussed (Arjamaa et al., 2009). Increasing evidences suggests that ROS and HIF-1α are 
directly involved in stimulating angiogenesis, both in tumours and in the retina (Al-
Shabrawey et al., 2008; Ushio-Fukai and Nakamura, 2008). ROS production may lead to 
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HIF activation and accelerated appearance of age-related diseases (Rapino et al., 2005; 
Yuan et al., 2008). ROS increases HIF protein expression and prevents the hydroxylation 
of HIF-1a protein (Yuan et al., 2008). These molecular responses ultimately lead to the 
increased expression of VEGF that is the major growth factor triggering choroidal 
neovascularization in the exudative AMD form (Schlingemann, 2004; Arjamaa et al., 
2009). 
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5. Aims 
Several recent studies highlight the interplay between UPP and autophagy pathways 
in several diseases (Pandey et al., 2007; Viiri et al., 2013; Zhang et al., 2014). However 
the mechanism by which ubiquitinated proteins are shuttled to autophagy lysosomal 
pathway remains still unclear.  
AMD is the leading cause of blindness in elderly people from western countries and 
its prevalence is rising as a consequence of longevity (Rattner and Nathans, 2006). 
Increasing data indicates a key role for the proteolytic pathways in the development of 
this disease (Arjamaa et al., 2009; Kaarniranta et al., 2013; Wang et al., 2009a), making 
AMD the perfect model to study the link between UPP, autophagy and exosomal removal 
of proteins. 
Thus, the general purpose of this study is to investigate the crosstalk between 
proteasome and autophagy proteolytic pathways in RPE cells in ageing-associated 
diseases such as AMD. We expect to identify the mechanisms and key players 
intrinsically linked to RPE dysfunction in AMD and how UPP and autophagy processes 
are involved.  
The work will focus on three main objectives: (i) to inhibit the proteasome-
dependent degradation of RPE cells through the use of MG-132  (ensured by ubiquitin 
conjugates and CDKN1A/p21 protein levels); (ii) to investigate the effect of proteasomal 
inhibition on autophagy (analysis of the autophagic markers LC3 (LC3-I e LC3-II), HIF-
1α and SQSTM1/p62) and lysosomal activity (by measuring the CatD protein levels); (iii) 
to establish an AMD cell line model, with RPE cells exhibiting concomitant proteasome 
impairment and autophagy enhancement, as it happens in AMD.  
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1. Materials 
 
The culture medium Dulbecco’s Modified Eagle’s Medium/ Ham’s F-12 
(DMEM:F12; 1:1) was obtained from Sigma-Aldrich (St Louis, MO, USA). Trypan blue 
(0.4%) solution, Fetal bovine serum (FBS), antibiotics (100 U/mL penicillin and 100 
μg/mL streptomycin) and Glutamax for cell culture were purchased from Gibco (Grand 
Island, NY, USA). Trypsin-EDTA (0.25%) was from Sigma-Aldrich (St Louis, MO, 
USA).  
N-(benzyloxycarbonyl)leucinylleucinylleucinal  (MG-132) was obtained from 
Calbiochem (La Jolla, CA, USA). Bafilomycin A1 (BafA1) and Cycloheximide (CHX) 
were purchased from Sigma-Aldrich (St Louis, MO, USA). Rapamycin was from 
Invitrogen (Camarillo, CA, USA).  
The DC Protein Assay used in total protein quantification was from Bio-Rad 
(Hercules, CA, USA).  
40% Acrylamide/Bis-acrylamide (29:1 solution) was purchased from NZYTech 
(Lisbon, Portugal). Other SDS-Page reagents and materials were from Bio-Rad 
Laboratories (Hercules, CA, USA), as well as the nitrocellulose (Nitrocellulose 
Membrane 0.45 μm, Bio-Rad) and polyvinylidene difluoride (PVDF) (Immun-blot PVDF 
membrane 0.20 μm, Bio-Rad) membranes. ClarityTM Western ECL substrate for detection 
of proteins was also from Bio-Rad.  
Hydrogen Peroxide (30% H2O2) was obtained from Merck Millipore (Darmstadt, 
Germany). 1x protease inhibitor cocktail was from Roche (Indianapolis, IN, USA) and 
Glycergel mounting medium from Dako (Carpinteria, CA, USA).  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), bovine serum 
albumin (BSA) and all other chemicals were purchased to Sigma-Aldrich (St Louis, MO, 
USA) and were of the highest purity available. 
 
 
2. Cell culture and treatments 
 
The spontaneously arising human retinal pigment epithelium cell line (ARPE-19) 
was obtained from LGC Promochem (Teddington, UK). Cultures of ARPE-19 cells were 
maintained in DMEM-F12 supplemented with 10% FBS, antibiotics (100 U/mL 
penicillin and 100 μg/mL streptomycin) and 1x Glutamax. The cell line was routinely 
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maintained at 37°C under 5% CO2 atmosphere and it was shown to exhibit features 
characteristic of RPE cells including defined cell borders and a cobblestone appearance. 
Upon reach confluency, adherent ARPE-19 cells were washed once with Phosphate-
buffered saline (PBS) and then trypsinized. The viable cells were counted using trypan 
blue, and a specific number of cells was plated.  
For Western blot and Immunocytochemistry assays, cells were seeded in 12 
multiwell plates (30,000 cells/well). For proteasome inhibition treatment, MG-132 was 
prepared in DMSO for stock solution at 10mM. One day after seeding, the cells were 
treated with 0.10 to 1.0μM of MG-132 freshly prepared in regular medium and incubated 
for 48h. 
In autophagic flux studies, a stock solution of BafA1 at 100μM in DMSO was 
prepared; the epithelial cells were incubated with 50nM of BafA1 for 1h and 6h. When 
the cells were co-treated with both MG-132 and BafA1, the last one was added in the last 
1h or 6h of the incubation with the proteasome inhibitor MG-132. The autophagy was 
induced with 30nM rapamycin freshly prepared, from a stock solution in DMSO at 
500μM, for 6h. Additionally, starvation was performed by removing the cell medium and 
culturing the cells in DMEM:F12 without FBS from 1h incubation up to 24h. 
Furthermore CHX, an inhibitor of protein biosynthesis in eukaryotic organisms 
(produced by the bacterium Streptomyces griseus), was prepared in Milli-Q water at 
5mg/mL, with the cells being exposed to 1μg/mL or 5μg/mL during the time of MG-132 
and BafA1 treatment.  
 
 
3. Cell metabolic activity 
 
Cell metabolic activity after MG-132 and BafA1 incubation was determined by 
measuring the ability of ARPE-19 cells to reduce MTT, to a colored insoluble formazan, 
being this reduction proportional to the mitochondrial enzyme succinate dehydrogenase 
activity. ARPE-19 cells seeded in a 96 well plate at a density of 10,000 cells /well were 
grown one day until they reached confluency. Then, the treatments were performed with 
the same concentrations and times used in the experiments previously described. H2O2 
was used as a positive control (final concentration of 1mM, for 2h). After the treatments, 
the medium was removed, the cells were washed twice with PBS and incubated with 0.5 
mg/ml MTT in cell medium for 4h at 37°C. Subsequently, supernatants were removed 
and the precipitated dye was dissolved in 200 μl 0.04 M HCl (in absolute isopropanol) 
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with agitation at room temperature until all the crystals were dissolved. They were 
quantified at a wavelength of 570 nm, using 620 nm wavelength as a background in the 
microplate reader (Synergy HT, Biotek, Winooski, VT, USA). Each experiment was done 
in quadruplicates of the different conditions. Cytotoxicity was determined by the 
following formula:  
 Cytotoxicity (%) = 
            –                         
            –                         
     
 
4. Protein Quantification 
 
Total protein concentration was determined using the Bio-Rad DC Protein Assay, a 
colorimetric assay based on the Lowry method. Briefly, BSA was used to generate a 
standard curve, by preparation of several dilutions of BSA in sample buffer in a range 
between 62.5  and 2000 μg/mL of BSA. In a 96 multi-well plate, the standard curve was 
prepared in duplicate, by adding into each well 5μL of the different BSA dilutions, 25μL 
of reagent A’ (49 parts of reagent A mixed with 1 part of reagent S) and 200μL of reagent 
B. The same procedure was performed for the samples and the blank (sample buffer), 
also in duplicates. The plate was incubated at 37°C for 30min. Then, the absorbance at 
655 nm was measured in the plate reader Biotek Synergy HT spectrophotometer. The 
protein concentration in the samples was directly obtained by plotting the average of the 
absorbance at 655 nm for each BSA standard in function of its concentration (μg/mL). 
 
5. Western blotting 
 
The cell lysates were prepared for the Western blot analysis. After treatments, the 
cells were rinsed twice with PBS, collected immediately in 50μL of 4x Laemmli Buffer 
(250mM Tris-HCl (pH 6.8), 35% (v/v) glycerol, 20% (v/v) β-mercaptoethanol, 8% (m/v) 
SDS, 0.03% (m/v) bromophenol blue) and boiled for 5min at 95ºC. In some experiments, 
namely in CHX assays, cells were collected in Radioimmunoprecipitation assay buffer 
(RIPA): 150mM NaCl, 50mM Tris-HCl (pH 7.5), 1% (v/v) NP-40, 0.1% (m/v) SDS, 
supplemented with 2 mM phenylmethylsulfonyl fluoride (PMSF), 10 mM iodoacetamide 
(IAM), 1 mM sodium orthovanadate and 1x protease inhibitor cocktail. Briefly, the cells 
in the 12 multi-well plates were rinsed twice with ice-cold PBS and then scraped and 
collected in 100μL of RIPA buffer after 15min of incubation on ice with agitation. After 
centrifugation (11,000g for 10min at 4°C) of the cell lysates, supernatants were used to 
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determine protein concentration and then were denatured with Laemmli buffer. The 
samples were boiled for 5min at 95°C and frozen at -20°C until use. 
For the western blot analysis, 20 to 50 μg of protein were loaded per lane and 
separated by electrophoresis on 10-15% polyacrylamide gel containing sodium dodecyl 
sulfate (SDS-PAGE). The electrophoresis was performed using Tris-HCl buffer (pH 8.0-
8.5), containing 0.4M Tris, 3.2 M glycine and 0.1% (m/v) SDS, at 140 V. 
After electrophoresis, proteins were electro-transferred to nitrocellulose or PVDF 
membranes. Western blot transfer was performed using 100 mM Tris-HCl (pH 7.5-8.0) 
containing 25 mM glycine, 20% (v/v) methanol and 0.01% (m/v) SDS, for 75min at 
100V, on ice with agitation. After transfer, membranes were blocked with 5% (m/v) 
nonfat milk in Tris-buffered saline (TBS) (50 mM Tris (pH 7.6) and 150 mM NaCl, 
containing 0.01% (v/v) Tween-20 (TBS-T)), for at least 30min under agitation, at room 
temperature. 
Membranes were incubated with primary antibodies (Table I) diluted in TBS-T 
supplemented with 5% non-fat milk, overnight at 4°C. On the following day, membranes 
were washed with TBS-T (3x10min) and then incubated with adequate horseradish 
peroxidase (HRP) conjugated secondary antibodies (Table I) with agitation for 1h, at 
room temperature. After secondary antibody incubation, membranes were washed again 
with TBS-T (3x 10min) and the immunoreactive bands were visualized with enhanced 
chemiluminescence (ECL) reagent. To confirm equal protein loading and sample transfer, 
blots were reprobed with mouse anti-α-tubulin or goat anti-GAPDH antibodies. 
Immunoreactive bands were revealed by scanning blots using a VersaDoc (Bio-Rad Life 
Science) imaging system. Exposure times were adjusted so that the band intensity fell 
within the linear range of detection. Densitometric analyses were performed using the 
ImageJ 1.47v software. 
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Table I – Primary and secondary antibodies for Western blot. 
 
Antibody Host Type Dilution Supplier 
anti-Ubiquitin (P4D1)  Mouse monoclonal 1:1000 Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA, USA)  
anti-HIF 1-α Rabbit polyclonal 1:1000 Santa Cruz Biotechnology, Inc.    
anti-p21  Rabbit polyclonal 1:100 Santa Cruz Biotechnology, Inc.    
anti-LC3 Rabbit polyclonal 1:500 Thermo Fisher Scientific Inc. 
(Waltham, MA, USA) 
anti-SQSTM1/p62  Mouse monoclonal 1:1000 Santa Cruz  Biotechnology, Inc    
anti-Cathepsin D Rabbit monoclonal 1:1000 GeneTex, Inc. (Irvine, CA, 
USA) 
anti-GAPDH Goat polyclonal 1:2500 Sicgen  (Coimbra, Portugal) 
anti-α-tubulin Mouse monoclonal 1:1000 Sigma-Aldrich Co.  
(St Louis, MO, USA) 
HRP secondary anti-
mouse  
Goat IgG (H+L) 1:5000 Bio-Rad (Hercules, CA, USA) 
HRP secondary anti-
rabbit  
Goat IgG (H+L) 1:5000 Bio-Rad 
HRP secondary anti-
goat 
Rabbit IgG (H+L) 1:5000 Invitrogen  
(Carlsbad, CA, USA) 
 
6. Immunocytochemistry 
 
As referred above, 30,000cells/well were seeded in a 12 well plate in glass coverslips 
(2 coverslips per well). The proteasome and lysosome inhibition (with MG-132 and 
BafA1, respectively) was performed as previously described. After treatment, cells were 
fixed with paraformaldehyde (PFA) 4% (v/v) in PBS for 10min and then washed with 
PBS (3x5min). After, cells were permeabilized with 0.2% (v/v) Triton X-100 in PBS for 
10min and rinsed again with PBS (3x5min). Next, the cells were blocked for 30min with 
2% (m/v) BSA and then incubated with the primary antibodies (Table II) in 0.02% (m/v) 
BSA for 1h30 at room temperature in a humidified chamber. After this, the cells were 
rinsed with PBS (3x10min) and incubated with the fluorophore-conjugated secondary 
antibodies (Table II) and 1μg/mL 4’,6-diamidino-2-phenylindole (DAPI), for 1h at room 
temperature in a humidified chamber in the dark. As negative control, coverslips were 
incubated only with the secondary antibodies in order to establish background 
fluorescence and non-specific staining of the antibodies. Finally the cells were washed 
with PBS (3x10min) and the slides were mounted with Glycergel mouting medium. The 
slides were stored at 4ºC in the dark until acquisition of images using the confocal 
fluorescence microscope (LSM 710, Carl Zeiss, Gottingen, Germany).  
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Table II – Primary and secondary antibodies for Immunocytochemistry  
 
Antibody Host Type Dilution Supplier 
anti-Ubiquitin (P4D1) Rabbit polyclonal 1:50 Boston Biochem  
(Cambridge, MA,USA) 
anti-SQSTM1/p62  Mouse monoclonal 1:100 Santa Cruz  Biotechnology, Inc. 
Alexa Fluor 488 anti-
rabbit  
Goat IgG (H+L) 1:100 Molecular Probes Inc.  
(OR, USA) 
Alexa Fluor 568 anti-
mouse 
Goat IgG (H+L) 1:100 Molecular Probes Inc.  
 
7. Statistical analysis 
 
Results were analyzed using GraphPad Prism (GraphPad Prism 5.0 software, La 
Jolla, CA, USA). They are presented as mean ± standard errors of the mean (S.E.M.) with 
n indicating the number of experiments. All the results are representative of at least three 
independent experiments. To test the significance of the difference between two 
independent groups, a Student’s t test followed by Mann-Whitney test was used. The 
comparison of values between more than two groups was performed using one-way 
analysis of variance (ANOVA), followed by Tukey’s multiple comparison test. A value 
of p<0.05 was considered to represent a significant difference. 
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1. MG-132-induced proteasome inhibition stimulates autophagy 
and increases lysosomal activity in ARPE-19 cells 
 
1.1. Proteasome inhibition increases ubiquitin and CDKN1A/p21 
levels 
 
ARPE-19 (Dunn et al., 1996) is a cell line commonly used as a model of human 
retinal epithelial cells (Dunn et al., 1998; Philp, 2003; A. L. Wang, Lukas, Yuan, Du, 
Tso, et al., 2009). This is a spontaneously arising human RPE cell line with normal 
karyology which forms epithelial stable monolayers, exhibiting morphological and 
functionally polarity. ARPE-19 has structural and functional properties characteristic of 
RPE cells in vivo: the cells express the RPE-specific markers CRALBP and RPE-65 
(Dunn et al., 1996; Dunn et al., 1998) making them a good model for in vitro studies of 
retinal pigment epithelium physiology (Ablonczy et al., 2011).   
To investigate whether proteasome inhibition affects the RPE, the ARPE-19 cells 
were treated with MG-132 (carbobenzoxy-Leu-Leu-leucinal), a peptide aldehyde that 
effectively blocks the proteolytic activity of the 26S proteasome complex (Ciechanover, 
1994; Lee & Goldberg, 1998; Fernandes et al., 2006). In order to mimic the chronic UPP 
inhibition that occurs in AMD (Shang & Taylor, 2012; Kinnunen et al., 2012), cells were 
exposed to various concentrations of MG-132 (0.1-1μM) for 48h.  
MG-132 cytotoxic effect was assessed by the MTT colorimetric assay (Figure 4.1). 
No significant cytotoxicity was observed when cells were incubated with MG-132 up to 
0.20uM. However, there was an increased cytotoxicity in a concentration time dependent 
manner, for increasing concentrations of MG-132 (0.50 and 1μM). H2O2 (1 mM) was 
used as a positive control in MTT assay, since it is known to be inducer of oxidative 
stress and thus compromising the cell membrane structure.   
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Figure 4.1 – Chronic treatment with MG-132 induces cytototixicy for concentrations higher than 0.20 
μM. ARPE-19 cells were treated with 0.10, 0.15, 0.20, 0.50 and 1.0μM of MG132 for 48h. Positive 
controls were performed adding 1mM hydrogen peroxide (30% H2O2) to ARPE-19 cells in the last 2h of 
the experiments. Cytotoxicity was evaluated by the MTT assay. Data are expressed as percentage of the 
control and represent the mean ± SEM of three independent experiments (each one was done in 
quadruplicates). ***p<0.001 significantly different from control, ### p<0.001 significantly different from 
0.20μM, 1way ANOVA followed by Tukey’s Multiple Comparison Test.  
 
To test whether the concentrations of MG-132 under analysis induce inhibition of the 
proteasome, western blot was performed to determine the amount of ubiquitinated 
proteins (Figure 4.2).  
There were no significant differences in the levels of the ubiquitin conjugates when 
cells were incubated with MG-132 up to 0.15 μM. However, there was a concentration-
dependent effect of MG-132 on ubiquitin conjugates for concentrations above 0.15 μM. 
ARPE-19 cells treated during 48h with 0.20μM of the proteasome inhibitor exhibited 
levels of ubiquitin conjugates significantly higher (3.959±0.547, p=0.0002) compared 
with control cells (1.000±0.069). For higher concentrations of MG132, the accumulation 
of ubiquitin conjugates was even greater.  
 
Figure 4.2 – Proteasome inhibition with 0.20μM of MG-132 led to accumulation of ubiquitin 
conjugates. ARPE-19 cells were treated with 0.10, 0.15, 0.20, 0.50 and 1.0μM of MG-132 for 48h. The 
protein levels of ubiquitin conjugates were assessed in total cell lysates by Western Blotting using specific 
antibodies against ubiquitin (P4D1 antibody). GAPDH was used as loading control. Data represent the 
mean ± SEM (n≥8 for each concentration), ***p<0.001 significantly different from control, Student’s t test 
followed by Mann-Whitney test.  
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Besides the accumulation of ubiquitin conjugates, we also confirmed the MG132-
induced proteasomal inhibition by analyzing the protein levels of the proteasome 
substrate cyclin-dependent kinase inhibitor 1A (CDKN1A/P21/Cip1) by Western 
Blotting (Figure 4.3).  
According to our hypothesis, proteasome inhibition induced CDKN1A/p21 
accumulation. The protein levels of CDKN1A/p21 were about 3 times higher at 0.20μM 
(3.121±0.666, p=0.0067) comparing with the control (1.000±0.03).  
 
 
 
Figure 4.3 – Effects of proteasome inhibition with MG-132 results in increased CDKN1A/p21 protein 
levels in ARPE-19 cells. ARPE-19 cells were treated with 0.10, 0.15, 0.20, 0.50 and 1.0μM of MG-132 for 
48h. The protein levels of CDKN1A/p21 were assessed in total cell lysates by Western Blotting against 
correspondent antibodies. GAPDH was used as loading control. All the results represent the mean ± SEM 
of at least four independent experiments. n.s. non-significant; *p < 0.05; **p < 0.01 significantly different 
from control, Student’s t test followed by Mann-Whitney test.  
 
 
1.2. MG-132-induced proteasomal inhibition leads to increased levels 
of autophagy markers  
 
Another mechanism for protein degradation is macroautophagy. This pathway 
usually shares its proteolytic burden with proteasomes during normal cellular 
homeostasis and protein clearance in response to cellular stress and the aging process 
(Kaarniranta, Salminen, Eskelinen, & Kopitz, 2009; Viiri et al., 2010). Recently, there 
has been an increased general interest in understanding the crosstalk between these 
proteolytic pathways (Kaarniranta et al., 2013;Lőw et al., 2013; Wojcik, 2013). 
In order to investigate whether proteasome inhibition could induce macroautophagy, 
we treated ARPE-19 cells with MG-132 exactly as performed in the previous studies and 
analyzed the autophagy marker LC3 by Western blot (Figure 4.4). As expected, 
endogenous LC3 was detected as two bands, one representing LC3-I, which is cytosolic 
and the other, LC3-II, which is conjugated with phosphatidylethanolamine (PE) and is 
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present on isolation membranes and autophagosomes, and much less on autolysosomes 
(Mizushima & Yoshimori, 2007)  
Interestingly, we found that when ARPE19 cells were incubated with increasing 
concentrations of MG-132 the amount of LC3-I decreased and that of LC3-II increased 
(Figure 4.4). LC3-II protein levels can be used as a measure of autophagy dynamics 
(Mizushima & Yoshimori, 2007). As shown in Figure 4.4, there was a significant 
increase in the levels of LC3-II when RPE cells were incubated with MG-132, for 
concentrations above 0.15μM: when the cells were exposed to 0.20μM of MG-132 
(2.041±0.237, p=0.0003) there was a significantly difference comparing with the control 
(1.000±0.03), which was even more evident when we considered higher concentrations. 
These results suggest upregulation of autophagosome formation or blockage of 
autophagic degradation. 
 
 
 
Figure 4.4 – Inhibition of the proteasome with MG-132 leads to increased LC3-II levels in ARPE-19 
cells. . ARPE-19 cells were treated with 0.10, 0.15, 0.20, 0.50 and 1.0μM of MG-132 for 48h. The protein 
levels of LC3 (LC3-I and LC3-II) were assessed in total cell lysates by Western Blotting. GAPDH was 
used as loading control. All the results represent the mean ± SEM of at least seven independent 
experiments. n.s. non-significant; ***p < 0.001 significantly different from control, Student’s t test 
followed by Mann-Whitney test. 
 
 
Our group has recently shown that the HIF-1α is degraded by alternative pathways, 
by the UPP or in the lysosome through CMA (Ferreira et al., 2013). Lysosomal 
inhibitors, but not macroautophagy inhibitors induce the accumulation of HIF-1α 
(Ferreira et al., 2013). STUB1, an ubiquitin ligase, is required for degradation of HIF-1α 
in the lysosome by CMA (Ferreira et al., 2013). 
In this context we measured the HIF-1α protein levels of RPE cells subjected to 
chronic proteasomal inhibition. Treatment of cells with increasing concentrations of MG-
132 for 48h decreased HIF-1α protein levels (Figure 4.5). This reduction was 
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significantly different above 0.20μM (0.356±0.01, p=0.0112), the same concentration that 
induced significant accumulation of LC3-II (Figure 4.4). This data suggests that HIF-1α 
may be degraded by another pathway than the UPP when ARPE-19 cells were incubated 
with MG-132 for 48h. 
 
 
Figure 4.5 – Proteasome inhibition with MG-132 decreases HIF-1α protein levels. ARPE-19 cells were 
treated with 0.10, 0.15, 0.20, 0.50 and 1.0μM of MG-132 for 48h. The protein levels of HIF-1α were 
assessed in total cell lysates by Western Blotting against correspondent antibodies. GAPDH was used as 
loading control. All the results represent the mean ± SEM of at least four independent experiments. n.s. 
non-significant; *p < 0.05 significantly different from control, Student’s t test followed by Mann-Whitney 
test.  
 
 
In order to investigate whether the increase in LC3-II and the decrease in HIF-1α 
observed upon proteasome inhibition is due to macroautophagy activation, we assessed 
the levels of another autophagy marker, the Sequestosome 1 (SQSTM1/p62). 
SQSTM1/p62 is one of the best known autophagic substrates and is therefore widely used 
as an indicator of autophagic degradation (Mizushima & Yoshimori, 2007; Sahani, 
Itakura, & Mizushima, 2014). It can interact with LC3, through its LC3-interacting region 
(LIR). SQSTM1/p62 is able to translocate not only to the phagophore membrane but also 
to the autophagosome formation site. Therefore, it is selectively incorporated into the 
autophagosome and then degraded (Pankiv et al., 2007; Sahani et al., 2014). 
Additionally, SQSTM1/p62 serves as a shuttling factor for the delivery of 
ubiquitinated substrates to the proteasome through its UBA domain (Seibenhener et al., 
2004). SQSTM1/p62 is also the best-characterized and ubiquitously expressed autophagy 
receptor that connects proteasomal clearance with lysosomes (Korolchuk, Menzies, & 
Rubinsztein, 2009; Viiri et al., 2013).  
In this context we evaluated the SQSTM1/p62 levels by Western blot (Figure 4.6A), 
as well as the distribution of SQSTM1/p62 and ubiquitin in treated ARPE-19 cells by 
Immunocytochemistry (Figure 4.6B). In our results, SQSTM1/p62 accumulated due MG-
132-induced proteasomal inhibition. The protein levels of SQSTM1/p62 were increased 
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in more than 10 times at 0.20μM (11.950±5.499, p=0.0117) comparing with non-treated 
cells (1.000±0.02).  
By Immunocytochemistry, we also observed an increased immunoreactivity for 
SQSTM1/p62, as well as for ubiquitinated proteins in MG-132 treated cells. Furthermore 
we assessed the localization of ubiquitin and SQSTM1/p62 within the cells, which 
showed a remarkable co-localization for these two proteins when exposed to 0.20μM of 
MG-132.  
 
 
 
Figure 4.6 – MG-132-induced proteasomal inhibition increases SQSTM1/p62 protein levels, which 
co-localize with ubiquitin conjugates. ARPE-19 cells were treated with 0.10, 0.15, 0.20, 0.50 and 1.0μM 
of MG-132 for 48h. (A) Protein levels of SQSTM1/p62 were measured in total cell lysates by Western 
Blotting. GAPDH was used as loading control. All the results represent the mean ± SEM of at least five 
independent experiments. n.s. non-significant; *p < 0.05 significantly different from control, Student’s t test 
followed by Mann-Whitney test. (B) Immunofluorescence microscopy analysis of untreated ARPE-19 cells 
and cells exposed to 0.20μM of MG-132 for 48h. Cells were immunostained with anti-ubiquitin (green) and 
anti-SQSTM1/p62 (red) antibodies. Nuclei are marked with DAPI. Original magnification 40x. The scale 
bar equals to 10μm.  
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1.3. Proteasomal inhibition leads to increased levels of Cathepsin D  
 
Many previous works have proposed that autophagy is associated with CatD (Hah et 
al., 2012; Wang, Lukas, Yuan, & Du, 2009). Cathepsins are the most studied lysosomal 
proteases that participate in autophagic degradation; in RPE cells the most abundant is 
cathepsin D (CatD) (A. L. Wang et al., 2009a). One essential step of autophagy is the 
fusion of autophagosomes with lysosomes, where CatD plays a key role as the major 
lysosomal protease in RPE cells. Moreover, it has been suggested that CatD might 
activate autophagy to enhance cell survival under oxidative stress (Hah et al., 2012). 
There are several forms of CatD including the precursors (the immature, inactive pre-pro-
cathepsin, 52 kDa and the intermediate pro-cathepsin, 48 kDa), and the mature form 
(mature, active, 34 and 14 kDa dimmer). We next investigated whether MG-132 
treatment altered the activity of lysosomal proteases.  
 
Based on Western blotting for CatD, we were able to detect the intermediate form 
(48 kDa) and the mature form (34 kDa) (Figure 4.7). Interestingly, the precursor forms of 
CatD increased after the MG-132 exposure in a dose-dependent manner up to 0.20μM 
(3.532±1.117, p=0.0143), in comparison with control (1.000±0.005). However, 
concentrations of MG-132 above 0.2μM significantly decreased the protein levels of 
CatD precursors. The mature form of CatD also exhibited the same tendency, but slightly 
than the precursor forms.  Only at 0.20μM of MG-132 (1.379±0.198, p=0.0473) the 
mature CatD levels were significantly different than the control (1.000±0.012).  
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Figure 4.7 –MG-132-induced proteasome inhibition induces increased CatD protein levels. ARPE-19 
cells were treated with 0.10, 0.15, 0.20, 0.50 and 1.0μM of MG-132 for 48h. The protein levels of precursor 
and mature forms were assessed in total cell lysates by Western Blotting against CatD antibody. GAPDH 
was used as loading control. All the results represent the mean ± SEM of at least six independent 
experiments. n.s. non-significant; *p < 0.05 significantly different from control, Student’s t test followed by 
Mann-Whitney test. 
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2. The role of autophagy activity in conditions of proteasome 
inhibition 
 
2.1. BafA1 does not alter MG-132-induced proteasomal inhibition 
 
Our data above strongly indicate that MG-132-induced proteasome inhibition leads 
to an increase in autophagy and lysosomal activity in ARPE-19 cells. To better 
understand the contribution of the autophagy-lysosomal pathway, we inhibited lysosomal 
function using BafA1, a specific inhibitor of vacuolar-type H
+
 ATPase. BafA1 blocks 
autophagic degradation but does not affect autophagosome formation (Yamamoto et al., 
1998).   
In this context, we exposed ARPE-19 cells to 0.20μM MG-132, since it was the 
lowest concentration that effectively inhibited proteasome activity and exhibited the most 
significant results in ubiquitin conjugates, CDKN1A and LC3 reported above studies. We 
examined the effects of MG-132 in the presence and absence of BafA1, which was added 
to cells in the last 6h or 1h of the experiment.  
As a first approach, we employed the MTT assay to assess cytotoxicity of BafA1 and 
MG-132 on ARPE-19 cells, as shown in Figure 4.8. The results obtained showed that 
these treatments did not induce cytotoxicity.  
 
                             
 
Figure 4.8 –Toxic effects of MG-132 and BafA1 on ARPE-19 cells. ARPE-19 cells were exposed to 
0.20μM MG-132 for 48h, in the presence or absence of 50nM BafA1 for 1h or 6h. Positive controls were 
performed adding 1mM H2O2 to non-treated cells in the last 2h of the experiments. Cytotoxicity was 
determined by MTT assay. Data are expressed as percentage of the control and represent the mean ± SEM 
of three independent experiments (each one was done in quadruplicates). *p < 0.05; ***p < 0.001 
significantly different from control, 1way ANOVA followed by Bonferroni´s Post-hoc test. 
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Then we wanted to explore the effect of the co-treatment of MG-132 and Baf1 on the 
ubiquitin conjugates and proteasome substrate CDKN1A/p21 in RPE cells. Therefore, we 
measured the protein levels of ubiquitin conjugates in ARPE-19 cells by Western blot, as 
shown in Figure 4.9.  
The results confirmed that MG-132 leads to an accumulation of ubiquitin conjugates, 
as we had previously observed. Moreover, BafA1 did not affect the formation of 
ubiquitin conjugates, since there were not significant differences between control 
(1.000±0.043) and BafA1 1h (1.341±0.093) or BafA1 6h (1.477±0.088). As expected, 
there were no significant differences in the levels of ubiquitin conjugates both when cells 
were exposed to MG-132+BafA1 for 1h (2.778±0.778) or 6h (2.953±0.678)  compared 
with cells exposed to MG-132 alone (2.935±0.430).  
 
 
Figure 4.9 –BafA1 does not alter ubiquitin conjugates formation. ARPE-19 cells were exposed to  
0.20μM MG-132 for 48h, in the presence or absence of 50nM BafA1 for 1h or 6h. The protein levels of 
ubiquitin conjugates were assessed in total cell lysates by Western Blotting against ubiquitin (P4D1 
antibody). GAPDH was used as loading control. All the results represent the mean ± SEM of at least five 
independent experiments. *p < 0.05; **p < 0.01 significantly different from control, 1way ANOVA 
followed by Bonferroni´s Post-hoc test.  
 
 
The protein levels of CDKN1A/p21 were also analyzed (Figure 4.10). As expected, 
CDKN1A/p21 accumulated when cells were exposed to MG-132, alone (3.284±0.551) or 
with BafA1 at both 1h (3.205±0.710) and 6h (3.473±0.438). However, there were no 
significant differences between control (1.000±0.024) and BafA1 1h (1.436±0.152) or 
BafA1 6h (1.616±0.276), suggesting that CDKN1A/p21 is not degraded by autophagy in 
ARPE-19 cells.  
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Figure 4.10 –CDKN1A/p21 is degraded by the proteasome in ARPE-19 cells. ARPE-19 cells were 
exposed to 0.20μM MG-132 for 48h, in the presence or absence of 50nM BafA1 for 1h or 6h. The protein 
levels of CDKN1A/p21 were assessed in total cell lysates by Western Blotting against correspondent 
antibodies. GAPDH was used as loading control. All the results represent the mean ± SEM of at least five 
independent experiments. *p < 0.05; **p < 0.01 significantly different from control, 1way ANOVA 
followed by Bonferroni´s Post-hoc test. 
 
 
2.2. Enhancement of autophagic flux by exposure of RPE cells to 
MG-132  
 
Our previous data showed that MG-132 led to an increase in autophagy, as revealed 
by the results of LC3-II (Figure 4.4), HIF-1α (Figure 4.5) and SQSTM1/p62 (Figure 4.6).  
In order to evaluate whether autophagy is regulated when the proteasome is inhibited, we 
exposed the cells both to MG-132 and BafA1 and assessed the levels of autophagic 
markers LC3-II and SQSTM1/p62, as well as HIF-1α. 
By Western blot, we evaluated the protein levels of LC3, as represented in Figure 
4.11. LC3-II protein levels, a measure of autophagy dynamics, are shown in the graphic. 
 Similarly to what previously observed, MG-132 induced autophagy. LC3-II doubled 
in cells exposed to MG-132 alone (2.103±0.286). Incubation of ARPE-19 cells with 
BafA1 for 1h (4.258±0.870) caused accumulation of LC3-II, which is even higher in MG 
+ Baf 1h (4.716±1.062). The same happened when the exposure time to BafA1 was 
extended to 6h, with the protein levels of LC3-II being significantly different from 
control (Baf 6h (6.720±1.014) and MG+Baf 6h (7.500±1.457)).  
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Figure 4.11 – Enhancement of autophagic flux by exposure of RPE cells to MG-132: measuring of 
autophagic marker LC3-II protein levels. ARPE-19 cells were exposed to 0.20μM MG-132 for 48h, in 
the presence or absence of 50nM BafA1 for 1h or 6h. The protein levels of LC3 (LC3-I and LC3-II) were 
assessed in total cell lysates by Western Blotting against the correspondent antibody. GAPDH was used as 
loading control. All the results represent the mean ± SEM of at least six independent experiments. **p < 
0.01; ***p < 0.001 significantly different from control, # p < 0.05; ## p < 0.01 significantly different from 
0.20μM MG-132, 1way ANOVA followed by Bonferroni´s Post-hoc test. 
 
 
Accordingly to our previous results, HIF-1α protein levels decreased when ARPE-19 
cells were exposed to MG-132 (0.523±0.088), comparing with control (1.000±0.001) 
(Figure 4.12). Incubation with BafA1 led to a considerable increase at 6h (5.399±1.177), 
which was diminished when the cell medium contained the proteasome inhibitor 
(4.443±1.056). For 1h of BafA1 the tendency is the same, but the levels of HIF-1α were 
not so high (Baf 1h (2.868±0.638) and MG + Baf1h (2.424±0.485)).  
 
 
 
Figure 4.12 – HIF-1α seems to be an autophagic substrate in RPE cells. ARPE-19 cells were exposed to 
0.20μM MG-132 for 48h, in the presence or absence of 50nM BafA1 for 1h or 6h. The protein levels of 
HIF-1α were assessed in total cell lysates by Western Blotting against correspondent antibodies. GAPDH 
was used as loading control. All the results represent the mean ± SEM of at least five independent 
experiments. *p < 0.05; **p < 0.01 significantly different from control, ### p < 0.001 significantly 
different from 0.20μM MG-132, 1way ANOVA followed by Bonferroni´s Post-hoc test. 
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In order to investigate the effect of MG-132 and BafA1 in SQSTM1/p62, its protein 
levels and distribution in the ARPE-19 cells were evaluated by Western blot and 
immunocytochemistry, respectively (Figure 4.13A and B).  
A significant increase in SQSTM1 levels was observed in RPE cells incubated with 
MG-132 (Figure 4.13A). The protein levels of SQSTM1/p62 were very similar in the 
cells were incubated with MG-132 alone (9.074±2.137) or in the presence of BafA1 
(MG+Baf1h (8.105±1.810) and MG+Baf6h (8.520±1.621)). The use of BafA1 prevented 
the autophagic flux, which seems to cause a slightly and probably time-dependent 
accumulation of SQSTM1/p62.  
Immunocytochemistry experiments performed in fixed ARPE-19 cells confirmed the 
previous results (Figure 4.13B). We observed an increased immunoreactivity for 
SQSTM1/p62, as well as for ubiquitinated proteins in MG-132 treated cells. In 
comparison to control cells, MG-132 induced an increased immunoreactivity for 
SQSTM1/p62 mainly in the nuclear/perinuclear compartment and also in the cytoplasm 
(Figure 4.13B). The localization of ubiquitin and SQSTM1/p62 showed a remarkable co-
localization for these two proteins in both BafA1 and MG-132 treatments, mainly at 
0.20μM of MG-132. In this condition the cells exhibit a strong punctate staining.  
In its turn, BafA1 led to reduced immunoreactivity for ubiquitin and SQSTM1/p62 
comparing with MG-132; however, the staining for these two proteins was higher than in 
the untreated cells. The use of the autophagy inhibitor caused a more diffuse staining; 
however the co-localization of the two proteins is still very evident.  
Additionally, we observed an intermediate situation when the cells were treated with 
both proteasome and lysosomal activity inhibitors. In this condition, immunofluorescence 
of ARPE-19 cells with ubiquitin and SQSTM1/p62 showed a less diffuse staining than 
when incubated only with BafA1. We identify several distinct bright spots of colocaliza-
tion for the two proteins, but the intensity of the signal is lower than with MG-132.  
To determine whether the observed accumulation in SQSTM1/p62 is due to an 
increase in the protein synthesis or a decrease in its degradation, we treated ARPE-19 
cells with MG-132 and/or BafA1 in the presence of the inhibitor of protein biosynthesis, 
CHX. SQSTM1/p62 protein levels were assessed by Western Blotting (Figure 4.13C). 
As previously observed, MG-132 induced an increase in SQSTM1/p62 protein 
levels, both in the presence or absence of BafA1. When we added the protein synthesis 
inhibitor CHX, this increase disappeared, indicating that an enhanced protein synthesis is 
the cause of MG-132-induced accumulation of SQSTM1/p62. This effect was observed 
either with 1μg/mL and 5μg/mL of CHX and appears to be CHX-concentration 
dependent. At 5μg/mL CHX the protein levels of SQSTM1/p62 were very similar to 
control.  
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Figure 4.13 – Proteasome inhibition leads to ubiquitin and SQSTM1/p62 perinuclear aggregates and 
the accumulation of SQSTM1/p62 is due to increased protein synthesis. ARPE-19 cells were exposed 
to 0.20μM MG-132 for 48h, in the presence or absence of 50nM BafA1 for 1h or 6h. (A) Protein levels of 
SQSTM1/p62 were measured in total cell lysates by Western Blotting. GAPDH was used as loading 
control. All the results represent the mean ± SEM of at least six independent experiments. **p < 0.01; ***p 
< 0.001 significantly different from control, 1way ANOVA followed by Bonferroni´s Post-hoc test. (B) 
Immunofluorescence microscopy analysis of untreated ARPE-19 cells and cells exposed to 0.20μM MG-
132 for 48h, in the presence or absence of 50nM BafA1 for 6h. Cells were immunostained with anti-
ubiquitin (green) and anti-SQSTM1/p62 (red) antibodies. Nuclei are marked with DAPI. Original 
magnification 40x. The scale bar equals to 10μm. (C) ARPE-19 cells incubated with 0.20μM MG-132 for 
48h and/or 50nM BafA1 for 6h were exposed to 1μg/mL and 5μg/mL of CHX during the time of MG-132 
and BafA1 treatment. The protein levels of SQSTM1/p62were assessed in total cell lysates by Western 
Blotting. GAPDH was used as loading control. All the results represent the mean ± SEM of at least three 
independent experiments.  ### p < 0.001 significantly different from control 0.20μM MG-132, 2way 
ANOVA followed by Bonferroni´s Post-hoc test.  
 
 
2.3. MG-132 and BafA1 induce increased levels of CatD precursors 
 
Based on our previous results, inhibition of the proteasome with 0.20μM MG-132 
led to an increase in both precursor and mature forms of CatD. At this concentration we 
found raised protein levels of autophagy markers LC3 and SQSTM1/p62. All the results 
pointed to a concomitant stimulation of autophagy and enhanced lysosomal activity 
induced by low concentration of the proteasome inhibitor MG-132.   
To test this hypothesis, we determined the protein levels of CatD forms when the 
cells were incubated with MG-132 and/or BafA1 (Figure 4.14). ARPE-19 cells exposed 
to MG-132 exhibited increased levels of CatD precursor (3.405±0.639) and mature form 
(1.286±0.123), although in this latter the difference to the control was very small. As 
expected, BafA1 did not alter CatD protein levels, since lysosome was alkalized and 
lysosomal activity impaired. Interestingly, co-treatment of cells induced a significant 
increase of CatD precursors levels in comparison to control cells, but no significant 
differences were observed when compared with MG-treated cells. In its turn, the mature 
form of CatD appeared to exhibit the same tendency. However, the differences are so 
slight that is difficult to ensure the MG-132-induced CatD increase, which may indicate 
an effort of the cell to enhance active CatD formation and thus improve lysosomal 
activity.   
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Figure 4.14 – Effect of MG-132 and BafA1 in lysosomal activity in ARPE-19 cells. ARPE-19 cells 
were exposed to 0.20μM MG-132 for 48h, in the presence or absence of 50nM BafA1 for 1h or 6h. The 
protein levels of precursor and mature forms were assessed in total cell lysates by Western Blotting against 
CatD antibody. GAPDH was used as loading control. All the results represent the mean ± SEM of at least 
six independent experiments **p < 0.01 significantly different from control; 1way ANOVA followed by 
Bonferroni´s Post-hoc test. 
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3. Concomitant autophagy activation and UPP inhibition in 
RPE cells as a model of AMD 
 
3.1. Autophagy activation with starvation and rapamycin 
 
In RPE cells, simultaneously with proteasome impairment, activation of autophagy 
has been described to play an important role in AMD development (A. L. Wang, Lukas, 
Yuan, Du, Handa, et al., 2009; A. L. Wang, Lukas, Yuan, Du, Tso, et al., 2009). Recent 
evidences suggest that these events are intrinsically linked with age, where inactivation of 
the proteasome leads to enhanced autophagy. Moreover, oxidative stress, hypoxia, the 
unfolded protein response or inflammation can activate autophagy, and are present in 
AMD pathology (Kaarniranta et al., 2013).  
 
In order to further explore the crosstalk between UPP and autophagy in RPE cells, 
we first examined the autophagy induced by starvation (by culturing cells in DMEM:F12 
without FBS) or rapamycin (a mTOR inhibitor). As a first approach, we determined the 
optimal conditions of starvation, by culturing the ARPE-19 cells in DMEM:F12 medium 
without FBS up to 24h. Autophagy markers LC3II and SQSTM1/p62 protein levels were 
analyzed by Western Blotting (Figure 4.15). Starvation induced LC3-II with a maximal 
accumulation at 6h, which indicates an activation of autophagy. However, above 6h of 
starvation (1.266±0.241), autophagy clearance was impaired since LC3-II levels 
decreased in a time-dependent manner. Accordingly, the autophagic substrate 
SQSTM1/p62 levels decreased in cells starved up to 6h (0.674±0.049); after this time 
point, the prolonged nutrient deprivation in RPE cells led to a time-dependent autophagy 
inhibition and consequent inefficient SQSTM1/p62 degradation.  
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Figure 4.15 – Serum starvation-triggered autophagy: time-course evaluation of autophagy by 
measuring the autophagic markers LC3-II and SQSTM1/p62 protein levels. ARPE-19 cells were 
cultured in serum-free medium for 3h, 6h, 8h, 12h and 24h. The protein levels of LC3 (LC3-I and LC3-II) 
and SQSTM1/p62 were assessed in total cell lysates by Western Blotting against the correspondent 
antibodies. GAPDH was used as loading control. All the results represent the mean ± SEM of at least three 
independent experiments, *p < 0.05, **p < 0.01 significantly different from control; 1way ANOVA 
followed by Bonferroni´s Post-hoc test. 
 
 
Next, we assessed the autophagic flux when cells were starved or incubated with 
rapamycin, by using BafA1 to block autophagic degradation and thus verify if the 
autophagy inducers caused enhanced autophagosome formation. Taking into account the 
previous results, starvation was performed by culture the RPE cells in serum-free medium 
for 6h. The protein levels of SQSTM1/p62 and LC3-II were measured by Western 
blotting, as shown in Figure 4.16.  
RPE cells treated with autophagy activators exhibited an increase in the autophagic 
flux. As expected, both starvation and rapamycin decreased the BafA1-induced 
SQSTM1/p62 accumulation, indicating an enhanced degradation of this protein in the 
presence of those activation inducers. Furthermore, LC3-II protein levels increased with 
BafA1, and a concomitant treatment with rapamycin or starvation resulted in even higher 
LC3-II protein levels. Starvation or rapamycin alone was also able to increase LC3-II 
levels comparing with the control, strongly indicating that these autophagy inducers 
effectively enhanced the autophagic flux.  
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Figure 4.16 – Enhancement of autophagic flux by exposure of RPE cells to starvation and 
rapamycin: measuring of autophagic markers SQSTM1/p62 and LC3-II protein levels. ARPE-19 cells 
were exposed to 30nM rapamycin or cultured in serum-free medium for 6h, in the presence or absence of 
50nM BafA1. The protein levels of SQSTM1/p62 and LC3 (LC3-I and LC3-II) were assessed in total cell 
lysates by Western Blotting against correspondent antibodies. GAPDH was used as loading control. All the 
results represent the mean ± SEM of at least four independent experiments. *p < 0.05; **p < 0.01; ***p < 
0.001 significantly different from control, 1way ANOVA followed by Bonferroni´s Post-hoc test. 
 
 
3.2. Simultaneous autophagy stimulation and UPP inhibition 
increases autophagic clearance but not SQSTM1/p62 
degradation in RPE cells 
 
 
Despite the known decline in autophagy clearance with aging (Cuervo, 2008), 
growing evidence suggests that RPE cells exhibit an autophagy enhancement in AMD (A. 
L. Wang et al., 2009a; A. L. Wang et al., 2009b). One possible explanation is the 
inducible nature of autophagic function and the presence of several compensatory 
adaptations within the system (Grune, Jung, Merker & Davies, 2004).  
One of the mechanisms that is responsible for the autophagy activation in AMD is 
the proteasomal inhibition. The decreased activity of proteasomal degradation as well as 
the reduced turnover rates during aging can expose proteins to age-related modifications, 
such as protein carbonyl formation and aggregation, which can increase the pressure on 
the autophagic system (Salminen & Kaarniranta, 2009). Moreover, autophagy clearance 
can be stimulated by oxidative stress, hypoxia and inflammation, all present in the 
pathophysiology of AMD (Kaarniranta et al., 2013).   
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In this context we exposed ARPE-19 cells simultaneously to both MG-132 and one 
of the tested autophagy inducers (rapamycin or starvation). In these conditions, we 
guarantee proteasomal inhibition and autophagy activation in RPE cells, as it occurs in 
AMD. SQSTM1/p62 and LC3 protein levels were assessed by Western blot and are 
represented in Figure 4.17.  
As previously observed, MG-132 revealed to induce autophagy. The increase on 
LC3-II protein levels in cells treated with MG-132 (1.385±0.086) is similar to that 
induced by rapamycin (1.451±0.152). Starvation was the most effective autophagy 
inducer (2.352±0.334). Concomitant treatment of RPE cells with MG-132 and starvation 
led to the highest LC3-II levels, indicating strong autophagy stimulation (3.103±0.381).  
As shown in our previous results, proteasomal inhibition with MG-132 led to an 
accumulation of SQSTM1/p62 (1.262±0.081), which is even more pronounced in RPE 
cells that were co-treated with autophagy inducers (MG+rap (1.709±0.071) and 
MG+starv (1.855±0.242)). Once more, the data suggest that although SQSTM1/p62 is an 
autophagic substrate, this protein is not degraded upon proteasome inhibition, even when 
autophagy is stimulated.  
 
Figure 4.17 – Upregulation of autophagy and accumulation of SQSTM1/p62 by simultaneously 
inhibiting the UPP and inducing autophagy in RPE cells.  ARPE-19 cells were exposed to 0.20μM MG-
132 for 48h, in the presence of 30nM rapamycin or cultured in serum-free medium for 6h. The protein 
levels of SQSTM1/p62 and LC3 (LC3-I and LC3-II) were assessed in total cell lysates by Western Blotting 
against correspondent antibodies. GAPDH was used as loading control. All the results represent the mean ± 
SEM of at least three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 significantly different 
from control, # p < 0.05; ## p < 0.01 significantly different from 0.20μM MG-132, 1way ANOVA 
followed by Bonferroni´s Post-hoc test. 
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Currently, although there are some therapies available to slow down the progression 
of the disease, there is no cure for AMD. In the case of geographic atrophy, there are no 
approved therapies, which is mainly due to the lack of suitable molecular targets. The 
formation and accumulation of drusens, particularly in the macula, is strongly correlated 
with the development and progression of the disease (Ambati et al., 2013). Over the past 
decades a significant effort has been made to understand the mechanisms underlying 
drusens biogenesis and the involvement of RPE in their formation. Despite the significant 
knowledge that has been gathered in the last years, the processes that lead to the 
formation of drusens remain relatively unknown.  
Most of the hypotheses have focused on oxidative stress and inflammation. Indeed, 
previous studies carried out in our lab have suggested that oxidative stress-induced a 
deregulation (inhibition) of the UPP in the RPE that in turn might contribute to the 
development of AMD (Fernandes, Ramalho & Pereira, 2006; Fernandes et al., 2008; 
Fernandes et al., 2009). Since the activity of the proteasome was shown to decrease upon 
ageing, it is conceivable that impairment of the proteasome-dependent degradation of 
ubiquitin conjugates leads to increased macroautophagy activity, by diverting UPP 
substrates to the lysosome. 
It is well established that the basal autophagic activity of living cells decreases with 
age (Marino et al., 2008). There is also an inactivation of the proteasome, probably 
induced by oxidative stress since the level of proteins modified by oxidation is increased 
(Louie et al., 2002; Shang and Taylor, 2012). Over the past years, accumulated evidence 
suggests that UPP decreases in AMD. Our group has shown that inactivation of UPP key 
mediators in RPE cells led them to acquire the phenotypic alterations associated with 
AMD, including the neovascular component (Fernandes et al., 2006). The misfolded and 
damaged proteins are not degraded by UPP, so they aggregate forming the drusen. This 
study aims to understand the molecular mechanisms and key players intrinsically linked 
to RPE dysfunction and to evaluate the crosstalk between UPP and autophagy in AMD. 
In this study, we have used ARPE-19 cells, the most common cell line in human RPE 
studies (Dunn et al., 1998; Philp, 2003; Wang, Lukas, Yuan, Du, Tso, et al., 2009). As a 
first approach, proteasomal inhibition was performed by adding to the cells a potent 
inhibitor of 26S proteasome complex, MG-132 to mimic the chronic UPP inhibition that 
occurs in AMD (Shang & Taylor, 2012; Kinnunen et al., 2012) Our results showed that 
treatment with 0.20 uM MG-132 for 48h does not induce any significant cytotoxic effect 
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and is able to induce  significant accumulation of ubiquitin conjugates. MG-132 can 
therefore block the enzymatic activity of the proteasome without affecting cell viability.   
With UPP impairment, the damaged and misfolded proteins that were marked with 
ubiquitin for proteasomal degradation are not degraded and then accumulate as ubiquitin 
protein conjugates. Besides the formation of ubiquitin conjugates, proteasome inhibition 
was also verified by the impaired degradation (and consequent increase in protein levels) 
of CDKN1A/p21, a known proteasome substrate.  
One of the main goals of this work was to investigate the effect of proteasomal 
inhibition in macroautophagy. LC3-II and Beclin-1, proteins necessary for 
autophagosome formation are commonly used as markers of autophagy. Bortezomib, a 
26S proteasome inhibitor approved for treating multiple myeloma, was shown to increase 
cellular levels of LC3-II and Beclin-1 proteins in human glioblastoma U251 and U87 
cells (Zhang et al., 2014), melanoma cells (Selimovic et al., 2013), several cell lines of 
head and neck squamous cell carcinoma (Li and Johnson, 2012) and human osteosarcoma 
(HOS) cells (Lou et al., 2013; Wojcik, 2013). This data indicate that inhibition of 
proteasomal activities used to induce cell death caused enhanced autophagy. Based on 
these data, we assessed the LC3-II protein levels of RPE cells subjected to chronic 
proteasomal inhibition. Our results show that LC3-II accumulates in cells incubated with 
MG-132, suggesting an MG-132-induced increase in autophagy. LC3 is, in fact, widely 
used to monitor autophagy, since LC3-II conversion is correlated with the number of 
autophagosomes. However, one should be very careful in the interpretation of the results 
of LC3 immunobloting, since there are several factors that affect autophagic activity and 
LC3 conversion: LC3-II itself is degraded by autophagy; the levels of LC3 –II at a certain 
time point do not indicate the autophagic flux. Therefore, it is important to measure the 
amount of LC3-II in the presence and absence of lysosomal protease inhibitors, as well 
as, the degradation of autophagic substrates.   
Recently our group has shown that HIF-1α can be degraded by alternative pathways 
(Ferreira et al., 2013). Besides being a well-established substrate of the UPP,  HIF-1α can 
also be targeted for degradation in the lysosome through CMA (Ferreira et al., 2013). 
This targeting is dependent on its interaction with the ubiquitin ligase STUB1 (co-
chaperone STIP1 homology and U-box containing protein 1), which mediates the 
ubiquitinylation and subsequent degradation of HIF-1α in an oxygen-independent manner 
(Bento et al., 2010). It was found that the human, mouse and rat HIF-1α all have the 
pentapeptide sequence biochemically related to the KFERQ motif, required for a protein 
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to be a substrate for CMA. This motif is responsible for direct HIF-1α to CMA by 
recruitment of HSPA8 and the STUB1, which targets proteins for ubiquitinylation and 
subsequent proteasomal degradation. The results from our lab show that STUB1 is 
required for degradation of HIF-1α by CMA, ultimately resulting in an increased 
interaction of HIF-1α with the CMA receptor LAMP2A (Ferreira et al., 2013). 
Lysosomal inhibitors, but not macroautophagy inhibitors induce the accumulation of 
HIF-1α (Ferreira et al., 2013). CMA-mediated degradation of HIF-1α is activated by 
nutrient deprivation, affecting the cell survival under hypoxic conditions (Ferreira et al., 
2013). 
Accordingly, we found reduced HIF-1α protein levels in RPE cells due proteasomal 
inhibition. HIF-1α decreased after the MG-132 exposure in a dose-dependent manner, 
being this reduction significantly different above 0.20μM. Taking this in account, we 
admit that HIF-1α may be degraded by another pathway than the UPP in RPE cells, 
probably by CMA.  
To ensure that the increase in LC3-II and reduction of HIF-1α protein levels 
observed upon proteasome inhibition are caused by macroautophagy activation, we 
assessed the levels of another autophagy marker, the SQSTM1/p62. SQSTM1/p62 is 
specifically degraded by autophagy (Komatsu et al., 2007; Pankiv et al., 2007). The 
protein possesses a short LC3-interacting region (LIR) that facilitates direct interaction 
with LC3 and GABARAP (Gamma-aminobutyric acid receptor-associated protein) 
family proteins. Because its degradation is dependent on autophagy, the level of p62 
increases in response to inhibition of autophagy (Bjørkøy et al., 2005). Accumulation of 
SQSTM1/p62 has been used as a marker for autophagy inhibition or defects in 
autophagic degradation (Bjørkøy, Lamark, & Johansen, 2006; Bjørkøy et al., 2005; 
Komatsu et al., 2007; Mizushima & Yoshimori, 2007). The protein accumulates in cells 
and tissues from autophagy-deficient mice (Komatsu et al., 2004; Nakai et al., 2007). 
SQSTM1/p62 is also used as a marker for autophagy induction (Klionsky & Abdalla, 
2012; Mizushima & Yoshimori, 2007; Tasdemir, Galluzzi, & Maiuri, 2008). 
SQSTM1/p62 contains an N-terminal Phox and Bem1 (PB1) domain for self-
oligomerization, where an acidic surface of one p62 PB1 domain binds to a basic surface 
in the next p62 PB1 domain. The PB1 domain seems to be needed for the autophagic 
degradation of SQSTM1/p62 (Lamark et al., 2003; Wilson et al., 2003).  
Although the proteasome inhibitor MG-132 induced accumulation of LC3-II, we 
verify that it significantly increased the autophagy-specific substrate SQSTM1/p62 
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protein levels in RPE cells. Accumulation of SQSTM1/p62 is concentration-dependent 
on MG-132 loading and was verified by both Western blotting and immunofluorescence.   
Interestingly, the protein levels of SQSTM1/p62 were restored when CHX (an 
inhibitor of protein synthesis) was added to the cells, suggesting that this increase in 
SQSTM1/p62 protein content was caused by an enhanced protein synthesis. This result is 
corroborated by Viiri et al. (2013) recent study, which reports up-regulation, at both 
mRNA and protein levels of ELAVL1/HuR (embryonic lethal, abnormal vision, 
Drosophila)-like 1 (Hu antigen R) under MG-132 treatment in ARPE-19 cells. 
ELAVL1/HuR protein is a post-transcriptional factor, which acts mainly as a positive 
regulator of gene expression by binding to specific mRNAs whose corresponding 
proteins are fundamental for key cellular functions. ELAVL1/HuR binds and post-
transcriptionally regulates SQSTM1/p62 mRNA in RPE cells (Viiri et al., 2013). 
Our next step was to investigate whether MG-132 treatment altered the activity of 
lysosomal proteases. We measured the protein levels of the most abundant lysosomal 
protease that participate in autophagic degradation in RPE cells, cathepsin D. CatD is 
essential in the fusion of autophagosomes with lysosomes, actively participating in the 
autophagic degradation within lysosomes. CatD has been characterized in RPE cells (Im 
& Kazlauskas, 2007), being its main responsibility the degradation of POS and rhodopsin 
into glycopeptides within the RPE lysosomes (el-Hifnawi, 1995; Kaarniranta et al., 
2013). Furthermore, there is evidence indicating that CatD stimulates autophagy 
activation to inhibit stress-induced cell death in cancer cells (Hah et al., 2012).  
As previously referred, there are several forms of cathepsin D including the 
precursors (the immature pre-pro-cathepsin, 52 kDa and the intermediate pro-cathepsin, 
48 kDa), and the mature form (mature, 34 and 14 kDa dimmer). We found increased 
levels of CatD precursors forms after exposure to growing concentrations of MG-132 up 
to 0.20μM, concentration from which the CatD precursors start to reduce. The same 
tendency was verified for CatD mature form. It is difficult to ensure MG-132-induced 
CatD increase, which may indicate an effort of the cell to enhance active CatD formation 
and thus improve lysosomal activity.  These findings suggest, once more, that MG-132-
induced proteasomal inhibition stimulates autophagy lysosomal pathway.  
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At this point, we observed an increase in endogenous LC3-II protein levels when 
proteasome was inhibited by MG-132. HIF-1α is reduced in RPE cells upon proteasomal 
inhibition, suggesting degradation by autophagy. The SQSTM1/p62 protein levels were 
also greater, in agreement with recent reports (Viiri et al., 2013). Immunocytochemistry 
analysis revealed that the number of SQSTM1/p62 puncta was substantially higher in 
ARPE-19 cells exposed with MG-132. Consistent with this, the protein levels of 
cathepsin D were significantly increased in ARPE-19 cells exposed to 0.20μM MG-132 
for 48h. Taken together, this data strongly indicate an enhanced autophagic activity and 
raised autophagic vacuoles in MG-132 treated cells.  
Increases in the prevalence of autophagic vacuoles can be caused by either an 
increase in autophagosome formation or a decrease in the lysosome-mediated removal. 
To identity the potential cause, we assessed the autophagic flux, comparing 
autophagosome prevalence in the presence and absence of lysosomal inhibition by 
BafA1. Thus, in co-treated cells, the proteasome is inhibited by MG-132 and lysosomes 
are alkalized due to BafA1 action. The fusion between the autophagosomes and the 
lysosomes is prevented, making that autophagosomes accumulate, which explains the 
increase in LC3-II and SQSTM1/p62 usually verified in the presence of BafA1.   
The co-treatment of RPE cells with both proteasomal and lysosomal inhibitors did 
not induce cytotoxicity. As expected, BafA1 did not alter ubiquitin conjugates formation. 
MG-132 caused similar accumulation of ubiquitin conjugates in the presence and absence 
of BafA1 in the two times points considered, 1h and 6h. The same occurred with 
CDKN1A/p21, which indicates that CDKN1A/p21 is not degraded by autophagy in RPE 
cells. 
As widely described (Klionsky & Abdalla, 2012; Mizushima & Yoshimori, 2007; 
Wang et al., 2009), the autophagic flux was assessed by measuring the LC3-II protein 
levels in co-treated RPE cells. Previous incubation with MG-132 before BafA1 treatment 
induced a slight non-significant increase in LC3-II protein levels, comparing with cells 
only treated with BafA1. This is the measure of autophagic flux (Klionsky & Abdalla, 
2012; Klionsky & Elazar, 2008; Mizushima & Yoshimori, 2007) and was observed both 
at 1h and 6h, when RPE cells exhibit higher LC3-II relative levels. Other studies reported 
an MG-132-induced increase in LC3-II levels (Viiri et al., 2013).   
The BafA1 treatment allowed us to determine that HIF-1α is an autophagic substrate 
in RPE cells. Incubation with BafA1 led to a considerable increase at 6h which was 
diminished when the cell medium contained the proteasome inhibitor. This is explained 
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by the MG-132-induced autophagy, which is responsible for starting the HIF-1α 
autophagic degradation and thus cause the slight reduce of HIF-1α protein levels in co-
treated RPE cells.  
To better understand the role of SQSTM1/p62 in the crosstalk between the two 
proteolytic systems, we analyzed the effect of concomitant treatment with MG-132 and 
BafA1 in SQSTM1/p62. As Viiri et al. previously reported, in our work SQSTM1/p62 
protein levels strongly also increases during exposure to MG-132 (Viiri et al., 2013).  
Interestingly, by immunocytochemistry, we observed that in comparison to control 
cells, MG-132 induced an increased immunoreactivity for ubiquitinated proteins mainly 
in the nuclear/perinuclear compartment and also in the cytoplasm. This result is consist 
with other studies that described the formation of structures known as ‘aggresomes’ 
(Driscoll & Chowdhury, 2012; Tan, Wong, & Dawson, 2008; Wojcik, 2013). 
Aggresomes are constituted by the accumulation of protein, often polyubiquitinated, 
which are prone to aggregate due proteasomal inhibition. These structures are 
predominantly present in perinuclear compartments. They are considered to be a place of 
selective autophagy of damaged proteins that are isolated from other cytoplasmic 
components (Kopito, 2000). With MG-132, SQSTM1/p62 and ubiquitinated proteins co-
localize almost completely and the immunoreactive puncta were very intense. 
Furthermore, SQSTM1/p62 exhibits similar staining pattern of the ubiquitin conjugates, 
both in experiments with different concentrations of MG-132 and co-treatment with MG-
132 and BafA1. These results suggest that SQSTM1/p62 binds to ubiquitinated proteins, 
constituting SQSTM1-ubiquitin aggresomes.  
According to our results, SQSTM1/p62 was found to be an ubiquitin-binding 
scaffold protein that colocalizes with ubiquitinated protein aggregates in many 
neurodegenerative diseases, liver diseases and myofibrillar myopathies (Kuusisto et al., 
2001,2007; Olive et al., 2008). It has been shown to be a missing link combining the 
functions of the proteasomal and lysosomal clearance systems (Korolchuk et al., 2009). 
This protein shuttles polyubiquitinated tau for proteasomal degradation (Babu, Geetha, & 
Wooten, 2005).  SQSTM1/p62 can interact with ubiquitinated proteins via the C-terminal 
ubiquitin-associated (UBA) domain, enabling non-covalent binding to ubiquitin or 
ubiquitinated substrate proteins (Seibenhener et al., 2004; Viiri et al., 2010). These 
complexes are then transported for clearance by proteasomes.   
The presence of UBA domain enables SQSTM1/p62 to act as a cargo adapter for 
ubiquitinated proteins that can be degraded by autophagy. Alternatively, ubiquitinated 
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complexes can be shuttled to lysosomes for autophagocytic degradation when 
proteasomes are impaired or overwhelmed, (Geetha and Wooten, 2002; Kirkin et al., 
2009a). SQSTM1/p62 is an adaptor for selective autophagy of ubiquitinated substrates, 
since it interacts with LC3 through its LIR region. Mutations in SQSTM1/p62 lacking 
this region resulted in the formation of inclusion bodies, structures that were also 
observed during autophagy-deficiency (Pankiv et al., 2007; Ichimura et al., 2008; Viiri et 
al., 2010). There is emerging evidence that the SQSTM1/p62-ubiquitin protein complexes 
are being targeted to autophagic degradation (Komatsu et al., 2007; Pankiv et al., 2007). 
In agreement, both SQSTM1/p62 and LC3 were shown to colocalize with mutant 
huntingtin aggregates. Such aggregates were recently shown to be degraded by autophagy 
(Ravikumar et al., 2002, 2004). Studies of conditional knockout mice of Atg7 
demonstrated that autophagy is needed for clearance of ubiquitin-positive aggregates 
(Komatsu et al., 2005).  
Our data suggest that SQSTM1/p62 may link poly-ubiquitinated proteins to the 
autophagic machinery. This function seems be dependent on both the polymerization of 
SQSTM1/p62 via the NH2 -terminal PB1 domain and polyubiquitin binding via the 
COOH-terminal UBA domain of SQSTM1/p62 (Bjørkøy et al., 2005; Pankiv et al., 
2007).   
It is presently unclear whether there is a specific recognition or targeting of 
polyubiquitinated protein aggregates by the autophagic machinery. In this study, we 
propose a mechanism of crosstalk between the proteolytic pathways in which 
SQSTM1/p62 as a key role. Perinuclear ubiquitin aggregates are promoted by MG-132, 
since the ubiquitin-marked proteins are not degraded when the proteasomal is inhibited. 
The ubiquitin conjugates bind to SQSTM1/p62, which is sequestered in these SQSTM1-
ubiquitin perinuclear aggresomes. In this context, SQSTM1/p62 can recruit ubiquitinated 
protein aggregates to the autophagosome through the LIR domain. To ensure cell 
survival, the RPE cells increase SQSTM1/p62 protein synthesis, which explains the 
accumulation of SQSTM1/p62 due proteasome impairment. Probably SQSTM1 and other 
transcript factors synthesis is also stimulated, in order to improve autophagy clearance of 
non-functional and damaged proteins. Others studies have proposed that SQSTM1/p62 
regulates the packing and transport of ubiquitinated, misfolded and aggregated proteins, 
and also non-functional cell organelles for clearance via autophagy in mammalian cells, 
corroborating our hypothesis (Kirkin et al., 2009b; Kuusisto, Suuronen & Salminen, 
2001).   
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In RPE cells, in parallel with proteasome inactivation occurs the activation of 
autophagy when in conditions of AMD (Wang, Lukas, Yuan, Du, Handa, et al., 2009; 
Wang, Lukas, Yuan, Du, Tso, et al., 2009). The evidence of this work suggests that these 
events are intrinsically linked, where the age-related inactivation of the proteasome leads 
to the increase of autophagy. During ageing, there is also an accumulation of damaged 
and non-degraded ubiquitinated proteins which may increase autophagy (Bhutto & Lutty, 
2012; Blasiak, Petrovski, & Veréb, 2011; Wang, Lukas, Yuan, Du, Tso, et al., 2009). 
Nowadays it is admitted that these ubiquitinated proteins can be degraded in lysosome by 
autophagy, which works as a compensatory mechanism. Despite the known decline in 
autophagy clearance with aging (Cuervo, 2008), autophagy enhancement in AMD is 
possible due the inducible nature of autophagic function and the presence of several 
compensatory adaptations within the system (Grune, Jung, Merker & Davies, 2004). 
Moreover oxidative stress, hypoxia, the unfolded protein response or inflammation can 
activate autophagy, and are present in AMD pathology (Kaarniranta et al., 2013).  
Taken this in mind, we improved our AMD cell line model by stimulating 
autophagy. Two different approaches were performed: autophagy induced by starvation 
or with rapamycin, an mTOR inhibitor. First, we verify by LC3-II and SQSTM1/p62 
protein levels that 6h was the time point in which RPE cells exhibits maximal serum 
starvation-triggered autophagy activation. RPE cells treated with autophagy activators 
exhibited an increase in the autophagic flux, as both starvation and rapamycin decreased 
the BafA1-induced SQSTM1/p62 accumulation. As expected, LC3-II accumulated with 
BafA1 (due impaired degradation caused by late autophagic inhibition) and a 
concomitant treatment with rapamycin or starvation resulted in increased LC3-II protein 
levels and thus increased autophagy clearance. Similar results were obtained by other 
authors with another autophagy activator, AICAR (Viiri et al., 2013).  
In order to establish an accurate cell model of AMD, ARPE-19 cells were exposed 
simultaneously to both MG-132 and one of the tested autophagy inducers (rapamycin or 
starvation). In these conditions, we guarantee proteasomal inhibition and autophagy 
activation in RPE cells, as it occurs in AMD (Handa, 2012; Mitter et al., 2012). The 
increase of LC3-II protein levels in cells treated with MG-132 was similar to that induced 
by rapamycin, suggesting that MG-132 can be seen as an autophagic activator. Starvation 
was the most effective autophagy inducer. Concomitant treatment of RPE cells with MG-
132 and starvation led to the highest LC3-II levels, indicating strong autophagy 
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stimulation. MG-132-induced proteasomal inhibition caused SQSTM1/p62 accumulation, 
which increased in RPE cells that were co-treated with autophagy inducers. Once more, 
our data suggest that although SQSTM1/p62 is an autophagic substrate (Bjørkøy et al., 
2009; Klionsky & Abdalla, 2012), this protein is not degraded upon proteasome 
inhibition, even when autophagy is stimulated.  
These results are supported by studies from other groups. Wang and collaborators 
verified an increase in autophagy and exocytic activity in aged RPE cells, as well as the 
presence of autophagic and exosomes markers (CD63, CD81 and LAMP2) in drusen 
(Wang, Lukas, Yuan, Du, Handa, et al., 2009; Wang, Lukas, Yuan, Du, Tso, et al., 2009). 
The high levels of exosomes are explained since RPE is responsible for the removal of 
damaged macromolecules. It is admitted that the aged RPE may increases its exocytic 
activity through exosomes (Wang, Lukas, Yuan, Du, Handa, et al., 2009; Wang, Lukas, 
Yuan, Du, Tso, et al., 2009). In this last study, focused in the effect of cigarette smoke in 
RPE, exosome markers (CD63, CD81 and LAMP2) were localized between RPE and the 
choroid from mice exposed to chronic cigarette smoke, which did not occur in control 
mice (Wang, Lukas, Yuan, Du, Handa, et al., 2009). Furthermore, a decline autophagic 
efficiency in the RPE is associated with the later pathological stages of AMD and cellular 
dysfunction (Rao et al., 2009).  
AlphaB-crystallin (αβ), a small heat shock protein associated with several 
neurodegenerative diseases, cancer and cardiomyopathies, was discovered to be secreted 
from ARPE-19 cells via exosomes (Bhat & Gangalum, 2011). Besides the exosome 
markers CD9 and CD63, ARPE-19 secreted exosomes contain high levels of activated 
signaling proteins, such as phosphorylated Akt (T308), VEGFR2 (Y951) or PDGFRβ 
(Y751) (Biasutto, Chiechi, Couch, Liotta, & Espina, 2013). Also in this study, these 
investigators found that ARPE-19 exosomes are highly rich in TLR3 (Toll-Like Receptor 
3), which was reported to be involved in angiogenesis suppression and retinal 
degeneration. Human choroidal neovascular membranes from AMD patients were shown 
to express TLR3 exclusively in RPE cells, thus suggesting a possible role of TL3 in 
AMD (Biasutto et al., 2013). More recently, Kang and collaborators were able to identify 
several exosomal proteins in the aqueous humor as novel biomarkers in patients with 
neovascular AMD (Kang et al., 2014).  
Overall, we proposed an in vitro model for AMD, in which the crosstalk between the 
two major proteolytic pathways was analyzed. One of the AMD features is the 
impairment of proteasomal activity, which results in accumulated polyubiquitinated 
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proteins in SQSTM1/p62-ubiquitin aggresomes. Proteasomal inhibition induces 
autophagy activation, through the action of SQSTM1/p62, which triggers 
polyubiquitinated proteins to autophagy clearance in the lysosome. However, with time 
lysosome becomes overloaded and signs of lysosomal dysfunction begin to appear, such 
as accumulation of lipofuscin and decreased activity of lysosomal enzymes. Thus 
damaged proteins cannot be degraded. We hypothesize that aged RPE releases 
intracellular proteins via exosomes and, therefore, this event contributes to formation and 
accumulation of drusen in AMD. Therefore, further studies investigating the mechanisms 
underlying exosomes release and accumulation of drusen, in particular in conditions of 
proteasome inhibition and autophagy activation that were used in this work, should aim at 
clarifying this issue. 
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The results presented in this study show that MG-132-induced proteasome inhibition 
leads to increased autophagy in RPE cells. The autophagic flux is enhanced and the 
lysosomal activity stimulated upon UPP impairment.  Although, we verified a 
significantly increase in the autophagy-specific substrate SQSTM1/p62 due stimulation 
of protein synthesis in the presence of MG-132. MG-132 induced the formation of 
SQSTM1/p62-ubiquitin aggresomes, mainly in the nuclear/perinuclear compartment. Our 
data strongly indicates a key role for SQSTM1/p62 in the crosstalk between UPP and 
autophagy. SQSTM1/p62 bind ubiquitinated proteins that delivers to the autophagy 
lysosomal pathway through its UBA- LIR-domains.  
In this work, we propose that impairment of the proteasome-dependent degradation 
of ubiquitin conjugates leads to increased macroautophagy activity, since SQSTM1/p62 
diverts UPP substrates to the lysosome. With time, the increased flux of substrates 
through macroautophagy would overload the lysosome leading to lysosomal dysfunction 
and accumulation of subcellular deposits containing unprocessed material, that are 
eventually expelled by exocytosis, thus forming the drusen. However, these last steps 
remain unproved and need to be clarified. Moreover, it is not likely that SQSTM1/p62 is 
the only protein responsible for the UPP-autophagy shuttling and thus other possible 
players must be investigated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CAPTER 6 
REFERENCES 
 
 
 
77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
References 
 
Ablonczy, Z. (2011). A functional profile of gene expression in ARPE-19 cells. 
Investigative Ophthalmology & Visual Science, 52(12), 8614–20. 
Adamis, A.P., Shima, D.T., Yeo, K.T., Yeo, T.K., Brown, L.F., Berse, B., D’Amore, 
P.A., Folkman, J. (1993). Synthesis and secretion of vascular permeability 
factor/vascular endothelial growth factor by human retinal pigment epithelial cells. 
Biochem. Biophys. Res. Commun. 193 (2), 631–638. 
Admyre, C., Johansson, S. M., Qazi, K. R., Filen, J. J., Lahesmaa, R., Norman, M., Neve, 
E. P., Scheynius, A., Gabrielsson, S. (2007). Exosomes with immune modulatory 
features are present in human breast milk. J Immunol. 179(3), 1969-78. 
Al-Shabrawey, M., Rojas, M., Behzadian, A. et al. (2008). Role of NADPH in retinal 
inflammation. Invest. Ophthalmol. Vis. Sci. 49, 3239–3244. 
Ambati, J., Ambati, B.K., Yoo, S.H., Ianchulev, S., Adamis, A.P. (2003a). Age-related 
macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. 
Ophthalmol. 48, 257-293. 
Ambati, J., Anand, A., Fernandez, S. et al, (2003b). An animal model of age-related 
macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 9(11), 
1390–1397.  
Ambati, J. and Fowler, B.J. (2012) Mechanisms of Age-Related Macular Degeneration. 
Neuron 75(1), 26-39. 
Arjamaa, O., Nikinmaa, M., Salminen, A., & Kaarniranta, K. (2009). Regulatory role of 
HIF-1alpha in the pathogenesis of age-related macular degeneration (AMD). 
Ageing Research Reviews, 8(4), 349–58.  
Arstila, A.U., Trump, B.F. (1969) Autophagocytosis: origin of membrane and hydrolytic 
enzymes. Virchows Arch B Cell Pathol Incl Mol Pathol 2, 85–90. 
Babu, J.R., Geetha, T., Wooten, M.W. (2005). Sequestosome 1/p62 shuttles poly-
ubiquitinated tau for proteasomal degradation. Journal of Neurochemistry 94, 192–
203. 
Beatty, S., Koh, H., Phil, M., Henson, D., Boulton, M., (2000). The role of oxidative 
stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 
45, 115–134. 
Bellingham, S., Guo, B.B., Coleman, B.M., Hill, A.F. (2012). Exosomes: vehicles for the 
transfer of toxic proteins associated with neurodegenerative diseases? Front. 
Physiol. 3(124).  
Benbrook, D.M., Long, A. (2012). Integration of autophagy, proteasomal degradation, 
unfolded protein response and apoptosis. Experimental Oncology 34(3), 286-297. 
Bento, C.F., Fernandes, R., Ramalho, J. et al. (2010). The chaperone-dependent ubiquitin 
ligase CHIP targets HIF-1α for degrada- tion in the presence of methylglyoxal. 
PLoS One 5(11), e15062.  
Bhat, S.P. and Gangalum, R.K. (2011). Secretion of αB-crystallin via exosomes - New 
clues to the function of human retinal pigment epithelium. Communicative & 
Integrative Biology 4(6), 739-741 (Article Addendum). 
79 
 
Bhutto, I. and Lutty, G. (2012). Understanding age-related macular degeneration (AMD): 
Relationships between the photoreceptor/retinal pigment epithelium/Bruch’s 
membrane/choriocapillaris complex. Molecular Aspects of Medicine 33, 295–317. 
Biasutto, L., Chiechi, A., Couch, R., Liotta, L.A., Espina, V. (2013). Retinal pigment 
epithelium (RPE) exosomes contain signaling phosphoproteins affected by 
oxidative stress. Experimental Eye Research 319(13), 2113-23.  
Bjørkøy, G., Lamark, T., Brech, A. (2005). p62/ SQSTM1 forms protein aggregates 
degraded by autophagy and has a protective effect on huntingtin- induced cell 
death. J Cell Biol 171, 603-14.  
Bjørkøy, G., Lamark, T., Johansen, T. (2006). p62/SQSTM1: a missing link between 
protein aggregates and the autophagy. Autophagy 2(2), 138-139 (Article 
Addendum). 
Bjørkøy, G., Lamark, T., Pankiv, S. et al. (2009). Monitoring autophagic degradation of 
p62/SQSTM1. Methods of enzymology, 452(8), 181-197. 
Blasiak, J., Petrovski, G., Veréb, Z. et al. (2014). Oxidative stress, hypoxia and 
autophagy in the neovascular processes of age-related macular degeneration 
(AMD). Biomed Res Int. 2014(2014), 768026.  
Bloom, J., Amador, V.;,Bartolini, F., DeMartino, G., Pagano, M. (2003) Proteasome-
Mediated Degradation of p21 via N-Terminal Ubiquitinylation. Cell 115, 71–82 
Bulteau, A.L., Verbeke, P., Petropoulos, I., Chaffotte, A.F., Friguet, B. (2001). 
Proteasome inhibition in glyoxal-treated fibroblasts and resistance of glycated 
glucose-6-phosphate dehydrogenase to 20 S proteasome degradation in vitro. J Biol 
Chem 276,  45662–45668. 
Burke, J.M., Hjelmeland, L.M. (2005). Mosaicism of the retinal pigment epithelium: 
seeing the small picture. Molecular Interventions. 5(4), 241-249. 
Carrard, G., Bulteau, A.L., Petropoulos, I., Friguet, B. (2002). Impairment of proteasome 
structure and function in aging. Int J Biochem Cell Biol 34, 1461–1474. 
Catarino, S., Bento, C.F., Brito, A., Murteira, E., Fernandes, A.F., Pereira, P. (2012) 
Regulation of the expression of interleukin-8 induced by 25-hydroxycholesterol in 
retinal pigment epithelium cells. Acta Ophthalmologica 90(6), 255-263.  
Chen, Y., Zeng, J., Zhao, C., Wang, K., Trood, E., Buehler, J., Weed, M., Kasuga, D., et 
al. (2011). Assessing susceptibility to age-related macular degeneration with 
genetic markers and environmental factors. Arch. Ophthalmol. 129, 344–351. 
Chopdar, A., Chakravarthy, U., Verma, D. (2003). Age related macular degeneration. 
BMJ.  326, 485-488. 
Chung, H.Y., Cesari, M., Anton, S., Marzetti, E., Giovannini, S., Seo, A.Y., Carter, C., 
Yu, B.P., Leeuwenburgh, C. (2009) Molecular inflammation: Underpinnings of 
aging and age-related diseases. Ageing Research Reviews 8, 18–30. 
Ciechanover, A. (1994). The ubiquitin-proteasome proteolytic pathway. Cell, 79(1), 12–
21. 
Ciechanover A. (2003). The ubiquitin proteolytic system and pathogenesis of human 
diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans 
31, 474-81.  
80 
 
Clemons, T.E., Milton, R.C., Klein, R., et al. (2005). Risk factors for the incidence of 
Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease 
Study (AREDS) AREDS Report No. 19. Ophthalmology 112(4), 533–539. 
Cockman, M.E., Masson, N., Mole, D.R. et al. (2000). Hypoxia inducible factor- alpha 
binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. 
Biol. Chem. 275, 25733–25741. 
Conde-Vancells, J., Rodriguez-Suarez, E., Embade, N., Gil, D., Matthiesen, R., Valle, 
M., Elortza, F., Lu, S. C., Mato, J. M., Falcon-Perez, J. M. (2008). Characterization 
and comprehensive proteome profiling of exosomes secreted by hepatocytes. J 
Proteome Res. 7(12), 5157-66. 
Cook, H.L., Patel, P.J. and Tufail, A. (2008). Age-related macular degeneration: 
diagnosis and management. British Medical Bulletin 85, 127–149. 
Crabb, J.W., Miyagi, M., Gu, X. et al. (2002) Drusen proteome analysis: an approach to 
the etiology of age-related macular degeneration. Proc. Natl. Acad. Sci. USA 
99(23), 14682–14687. 
Cuervo, A.M. (2008). Autophagy and aging: keeping that old broom working. Trends 
Genet. 24, 604–612 
Cuervo, A.M., Dice, J.F. (1996). A receptor for the selective uptake and degradation of 
proteins by lysosomes. Science 273, 501– 503. 
Curcio, C.A. (2001). Photoreceptor topography in ageing and age-related maculopathy. 
Eye (Lond.) 15(3), 376–383. 
Dawson, T.M., Dawson, V.L., (2003). Molecular pathways of neurodegeneration in 
Parkinson’s disease. Science 302, 819-822. 
de Jong, P.M. (2006). Age-related macular degeneration. N. Engl. J. Med. 355, 1474–
1485. 
Del Priore, L.V., Kuo, Y.H., Tezel, T.H., (2002). Age-related changes in human RPE cell 
density and apoptosis proportion in situ. Invest. Ophthalmol. Vis. Sci. 43(10), 
3312–3318. 
Delori, F.C., Goger, D.G., Hammond, B.R., Snodderly, D.M., Burns, S.A. (2001). 
Macular pigment density measured by autofluorescence spectrometry: comparison 
with reflectometry and heterochromatic flicker photometry. J. Opt. Soc. Am. A. Opt. 
Image Sci. Vis. 18(6), 1212–1230. 
Ding, X., Patel, M., Chan, C.C. (2009). Molecular pathology of age-related macular 
degeneration. Prog Retin Eye Res 28, 1-18. 
Donoso, L. A., Kim, D., Frost, A., Callahan, A., and Hageman, G. (2006). The role of 
inflammation in the pathogenesis of age-related macular degeneration. Surv. 
Ophthalmol. 51, 137–152. 
Driscoll, J.J., Chowdhury, R.D. (2012) Molecular crosstalk between the proteasome, 
aggresomes and autophagy: translational potential and clinical implications. Cancer 
Letters 325(2), 147–154.  
Dudek, E. J., Shang, F., Valverde, P., Liu, Q., Hobbs, M., and Taylor, A. (2005). 
Selectivity of the ubiquitin pathway for oxidatively modified proteins: relevance to 
protein precipitation diseases. FASEB J. 19, 1707–1709. 
81 
 
Dunn, K C; Aotaki-Keen, A E; Putkey, F R; Hjelmeland, L. M. (1996). ARPE-19, A 
Human Retinal Pigment Epithelial Cell Line with Differentiated Properties. 
Experimental Eye Research, 62(2), 155–170. 
Dunn, K. C., Marmorstein, a D., Bonilha, V. L., et al. (1998). Use of the ARPE-19 cell 
line as a model of RPE polarity: basolateral secretion of FGF5. Invest. Ophthalmol. 
Vis. Sci., 39(13), 2744–9.  
el-Hifnawi, E. (1995). Localization of cathepsin D in rat ocular tissues. An immuno-
histochemical study. Ann Anat 177(1), 11-17. 
Eskelinen, E.L., Saftig, P. (2009) Autophagy: a lysosomal degradation pathway with a 
central role in health and disease. Biochim Biophys Acta 1793, 664-673.  
Ethen, C. M., Hussong, S. A., Reilly, C., Feng, X., Olsen, T. W., Ferrington, D. A. 
(2007). Transformation of the proteasome with age-related macular degeneration. 
FEBS Lett. 581, 885–890. 
Evans, J., (2008). Antioxidant supplements to prevent or slow down the progression of 
AMD: a systematic review and meta-analysis. Eye (Lond.) 22(6), 751–760. 
Fernandes, A.F., Bian, Q., Jiang, JK., Thomas, C. J., Pereira., P., Shang, F. (2009) 
Proteasome inactivation promotes mitogen-activated protein kinase-depedent 
phosphatidylinositol 3-kinase activation and increases interleukin-8 production in 
retinal pigment epitelial cells. Molecular Biology of the Cell 20, 3690–3699.  
Fernandes, A. F., Guo, W., Zhang, X. et al. (2006). Proteasome-dependent regulation of 
signal transduction in retinal pigment epithelial cells. Experimental Eye Research, 
83(6), 1472–81.  
Fernandes, A.F., Pereira, P. (2007) Oxidative Stress, Inflammation and Age-Related 
Macular Degeneration: a Bizarre Love Triangle. Exp. Ophthalmol.33(1), 1-8. 
Fernandes, A. F., Zhou, J., Zhang, X., Bian, Q., Sparrow, J., Taylor, A., Pereira, P., and 
Shang, F. (2008). Oxidative inactivation of the proteasome in retinal pigment 
epithelial cells. A potential link between oxidative stress and up- regulation of 
interleukin-8. J. Biol. Chem. 283, 20745–20753 
Fernandes, R., Ramalho, J., Pereira, P. (2006). Oxidative stress upregulates the ubiquitin 
proteasome pathway in retinal endotelial cells. Molecular Vision 12, 1526-35 
Ferreira, J. V., Fôfo, H., Bejarano, E. et al. (2013). STUB1/CHIP is required for HIF1A 
degradation by chaperone-mediated autophagy. Autophagy, 9(9), 1349–66.  
Friedman, D.S., O’Colmain, B.J. et al. (2004). Prevalence of age-related macular 
degeneration in the United States. Arch Ophthalmol 122, 564-572. 
Gamerdinger, M., Hajieva, P., Kaya, A. M. et al. (2009). Protein quality control during 
aging involves recruitment of the macroautophagy pathway by BAG3. The EMBO 
Journal, 28(7), 889–901.  
Gartel, A.L., Radhakrishnan, S.K. (2005). Lost in transcription: p21 repression, 
mechanisms, and consequences. Cancer Res. 65(10), 3980–5. 
Geetha, T., Wooten, M.W. (2002) Structure and functional properties of the ubiquitin 
binding protein p62. FEBS Lett 512, 19-24. 
Glickman, M.H., Ciechanover, A., (2002). The ubiquitin-proteasome proteolytic 
pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428. 
82 
 
Gong, J., Sagiv, O., Cai, H., Tsang, S.H., Del Priore, L.V. (2008). Effects of extracellular 
matrix and neighboring cells on induction of human embryonic stem cells into 
retinal or retinal pigment epithelial progenitors. Exp. Eye Res. 86(6), 957–965. 
Grune, T., Jung, T., Merker, K., Davies, K. J. A. (2004). Decreased proteolysis caused by 
protein aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and 
‘‘aggresomes’’ during oxidative stress, aging, and disease. Int. J. Biochem. Cell 
Biol. 36, 2519–2530. 
Gu, S-M., Thompson, D.A., Srikumari, C. et al. (1997). Mutations in RPE65 cause 
autosomal recessive childhood-onset severe retinal dystrophy. Nat. Genet. 17, 194–
197. 
Guertin, D.A., Stevens, D.M., Saitoh, M. et al. (2009). mTOR complex 2 is required for 
the development of prostate cancer induced by Pten loss in mice". Cancer 
Cell 15(2), 148–59. 
Guyer, D.R., Fine, S.L. et al. (1986). Subfoveal choroidal neovascular membranes in age-
related macular degeneration. Visual prognosis in eyes with relatively good initial 
visual acuity. Arch. Ophthalmol. 104, 702–705. 
Hageman, G. S, Mullins, R. F., Russell, S. R., Johnson, L. V.Anderson, D. H. (1999). A 
common haplotype in the complement regulatory gene factor H (HF1/CFH) 
predisposes individuals to age-related macular degeneration. FASEB J. 13, 477–
484. 
Haglund, K., Dikic, I., (2005). The role of ubiquitylation in receptor endocytosis and 
endosomal sorting. J. Cell Sci. 125(2) 265–275.  
Hah, Y-S., Noh, H. S., Ha, J. H. et al. (2012). Cathepsin D inhibits oxidative stress-
induced cell death via activation of autophagy in cancer cells. Cancer Letters, 
323(2), 208–14.  
Handa, J.T. (2012). How does the macula protect itself from oxidative stress? Molecular 
Aspects of Medicine 33, 418–435.  
Hayashi-Nishino, M., Fujita, N., Noda, T. et al. (2009). A subdomain of the endoplasmic 
reticulum forms a cradle for autophagosome formation. Nat Cell Biol 11, 1433–7.  
Hicke, L., (2001). A new ticket for entry into budding vesicles-ubiquitin. Cell 106(5), 
527–530. 
Hicke, L., Dunn, R. (2003). Regulation of membrane protein transport by ubiquitin and 
ubiquitin-binding proteins. Annual Review of Cell and Developmental Biology 19, 
141-172. 
Hope, A. D., de Silva, R., Fischer, D. F., Hol, E. M., van Leeuwen, F. W., Lees, A. J. 
(2003). Alzheimer’s associated variant ubiquitin causes inhibition of the 26S 
proteasome and chaperone expression. J. Neurochem. 86, 394–404. 
Hu, X., Du, C., Yang, L. (2010). Proteasome inhibitor MG132 suppresses number and 
function of endothelial progenitor cells: involvement of nitric oxide synthase 
inhibition. Internat. Journal of Molecular Medicine, 25(3) 385–392.  
Huang, S., Bjornsti, M., & Houghton, P. J. (2003). Rapamycins: mcehanism of actions 
and cellular resistance. Cancer Biology & Therapy, 2(June), 222–232. 
Ichimura, Y., Kirisako, T., Takao, T. et al. (2000). A ubiquitin-like system mediates 
protein lipidation. Nature 408, 488–92.  
83 
 
Ichimura, Y., Kumanomidou, T., Sou, Y.S. et al. (2008). Structural basis for sorting 
mechanism of p62 in selective autophagy. J Biol Chem 283, 22847-57. 
Ihara, Y., Morishima-Kawashima, M., Nixon, R. (2012). The ubiquitin-proteasome 
system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring 
Harb Perspect Med. 2(8).  
Im, E., Kazlauskas, A. (2007). The role of cathepsins in ocular physiology and pathology. 
Exp Eye Res 84, 383-8. 
Iwasaki, M., Inomata, H. (1988). Lipofuscin granules in human photoreceptor cells. 
Invest Ophthalmol Vis Sci. 29, 671–679.  
Jacinto, E., Facchinetti, V., Liu, D. et al. (2006). SIN1/MIP1 maintains rictor-mTOR 
complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 
127, 125–137. 
Jager, R.D., Mieler, W.F., Miller, J.W. (2008). Age-Related Macular Degeneration. N 
Engl J Med. 358, 2606-2617. 
Johnson, L.V., Leitner, W.P., Staples, M.K., Anderson, D.H. (2001). Complement 
activation and inflammatory processes in drusen formation and age related macular 
degeneration. Exp Eye Res 73, 887–896.  
Jung, C.H., Ro, S.H., Cao, J. et al. (2010). mTOR regulation of autophagy. FEBS Lett. 
584, 1287–1295. 
Jung, T., Catalgol, B., Grune, T. (2009). The proteasomal system. Mol Aspects Med 30, 
191-296. 
Kaarniranta, K., Salminen, A., Eskelinen, E.-L., Kopitz, J. (2009). Heat shock proteins as 
gatekeepers of proteolytic pathways—Implications for age-related macular 
degeneration (AMD). Ageing Research Reviews, 8(2), 128–139.  
Kaarniranta, K., Sinha, D., Blasiak, J. et al. (2013). Autophagy and heterophagy 
dysregulation leads to retinal pigment epithelium dysfunction and development of 
age-related macular degeneration. Autophagy, 9(7), 973–84.  
Kaarniranta, K., Hyttinen, J., Ryhanen, T. et al. (2014). Mechanisms of protein 
aggregation in the retinal pigment epithelial cells. Journal of the Society for Vector 
Ecology, 39(1), ii–iii.  
Kamada, Y., Funakoshi, T., Shintani, T. et al. (2000). Tor-mediated induction of 
autophagy via na Apg1 protein kinase complex. J Cell Biol. 150, 1507-13.  
Kamura, T., Sato, S., Iwai, K. et al. (2000). Activation of HIF-1alpha ubiquitination by a 
reconstituted von Hippel- Lindau (VHL) tumor suppressor complex. Proc. Natl. 
Acad. Sci. U.S.A. 97, 10430–10435. 
Kang,G., Bang,J.Y., Choi, A.J.,Yoon, J., Lee, W.C., Choi, S.,Yoon, S., Kim, H.C., Baek, 
J.H., Park, H.S., Lim, H.J., Chung, H. (2014). Exosomal Proteins in the Aqueous 
Humor as Novel Biomarkers in Patients with Neovascular Age-related Macular 
Degeneration Journal of Proteome Research 13(2), 581-595. 
Kannan, R., Zhang, N., Sreekumar, P.G., Spee, C.K., Rodriguez, A., Barron, E., Hinton, 
D.R. (2006) Stimulation of apical and basolateral VEGF-A and VEGF-C secretion 
by oxidative stress in polarized retinal pigment epithelial cells. Mol Vis. 12, 1649-
1659. 
84 
 
Kapphahn, R. J., Bigelow, E. J., Ferrington, D. A. (2007). Age-dependent inhibition of 
proteasome chymotrypsin-like activity in the retina. Exp. Eye Res. 84, 646–654. 
Katzmann, D.J., Odorizzi, G., Emr, S.D. (2002). Receptor down- regulation and 
multivesicular-body sorting. Nat Rev Mol Cell Biol 3, 893-905. 
Kawaguchi, T., Miyazawa, K., Moriya, S., et al. (2011). Combined treatment with 
bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces 
endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, 
autophagy-lysosome and ER stress. Int J Oncol 38, 643–54.  
King, R.W., Deshaies, R.J., Peters, J-M., Kirschner, M.W. (1996). How proteolysis 
drives the cell cycle. Science. 274, 1652–1658. 
Kinnunen, K., Petrovski, G., Moe, M. C., Berta, A., Kaarniranta, K. (2012). Molecular 
mechanisms of retinal pigment epithelium damage and development of age-related 
macular degeneration. Acta Ophthalmologica, 90(4), 299–309.  
Kirkin, V., McEwan, D.G., Novak, I., Dikic, I. (2009a) A role for ubiquitin in selective 
autophagy. Mol Cell 34, 259-69. 
Kirkin, V., Lamark, T., Sou, Y.S. et al. (2009b). A role for NBR1 in autophagosomal 
degradation of ubiquitinated substrates. Mol Cell 33, 505-516. 
Klein, R., Klein, B.E., Linton, K.L., (1992). Prevalence of age-related maculopathy. The 
Beaver Dam Eye Study. Ophthalmology 99 (6), 933–943.  
Klionsky, D.J., Abdalla, F.C., Abeliovich, H. et al. (2012). Guidelines for the use and 
interpretation of assays for monitoring autophagy. Autophagy 8(24), 445-544. 
Klionsky, D.J., Cregg, J.M., Dunn, W.A. Jr. et al. (2003). A unified nomenclature for 
yeast autophagy-related genes. Dev Cell 5, 539–45.  
Klionsky, D.J., Elazar, Z., Seglen, P.O., Rubinsztein, D.C. (2008). Does bafilomycin A1 
block the fusion of autophagosomes with lysosomes? Autophagy 4, 849–50. 
Kloetzel, P. M. (2004). Generation of major histocompatibility complex class I antigens: 
functional interplay between proteasomes and TPPII. Nat. Immunol. 5, 661–669. 
Koepp, D.M., Harper, J.W., Elledge, S.J. (1999). How the cyclin became a cyclin: 
regulated proteolysis in the cell cycle. Cell 97, 431–434. 
Komatsu, M., Waguri, S., Koike, M. et al. (2007). Homeostatic levels of p62 control 
cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131, 1149–
1163. 
Komatsu, M., Waguri, S., Ueno, T. et al. (2005). Impairment of starvation-induced and 
constitutive autophagy in Atg7-deficient mice. J. Cell Biol. 169, 425– 434. 
Kopito, R.R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends Cell 
Biol 10, 524–530. 
Korolchuk, V., Menzies, F., Rubinsztein, D. (2009). A novel link between autophagy and 
the ubiquitin-proteasome system. Autophagy, 5(6), 862–863.  
Korolchuk, V., Menzies, F., Rubinsztein, D. (2010). Mechanisms of cross-talk between 
the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Letters, 584(7), 
1393–8.  
Krohne, T.U., Stratmann, N.K., Kopitz, .J, Holz, F.G. (2010). Effects of lipid peroxida- 
tion products on lipofuscinogenesis and autophagy in human retinal pigment 
epithelial cells. Exp Eye Res 90, 465–471. 
85 
 
Kunchithapautham, K., Rohrer, B. (2007). Apoptosis and autophagy in photoreceptors 
exposed to oxidative stress. Autophagy 3, 433–441.  
Kuusisto, E., Kauppinen, T., Alafuzoff, I. (2008). Use of p62/SQSTM1 antibodies for 
neuropathological diagnosis. Neuropathol. Appl. Neurobiol. 34, 169–180. 
Kuusisto, E., Suuronen, T., Salminen, A. (2001). Ubiquitin-binding protein p62 
expression is induced during apoptosis and proteasomal inhibition in neuronal cells. 
Biochem Biophys Res Commun 280, 223-228. 
Lamark, T., Johansen, T. (2010). Autophagy: links with the proteasome. Current Opinion 
in Cell Biology, 22(2), 192–8.  
Lamark, T., Perander, M., Outzen, H., Kristiansen, K., 1vervatn, A., Michaelsen, E., 
Bjørkøy, G., and Johansen, T. (2003). Interaction codes within the family of 
mammalian Phox and Bem1p domain-containing proteins. J. Biol. Chem. 278, 
34568–34581. 
Lee, D. H., Goldberg, A. L. (1998). Proteasome inhibitors: valuable new tools for cell 
biologists. Trends in Cell Biology, 8(10), 397–403. 
Leger, F., Fernagut, P.O., Canron, M.H. et al (2011). Protein aggregation in the aging 
retina. J. Neuropathol. Exp. Neurol. 70(1), 63–68.  
Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., Ferrara, N. (1989). Vascular 
endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–
1309. 
Li, C., Johnson, D.E. (2012). Bortezomib induces autophagy in head and neck squamous 
cell carcinoma cells via JNK activation. Cancer Lett. 314, 102–107. 
Li, M., Khambu, B., Zhang, H, Kang, J.H., Chen, X. et al. (2013). Suppression of 
lysosome function induces autophagy via a feedback downregulation of mTORC1 
activity. J. Biol. Chem. 288(50), 35769-35780. 
Li, W.W., Li, J., Bao, J.K. (2012). Microautophagy: lesser-known self-eating. Cell Mol 
Life Sci 69, 1125–36.  
Li, Y.,Wang, Y.S., Shen, X.F. et al. (2008). Alterations of activity and intracellular 
distribution of the 20S proteasome in ageing retinal pigment epithelial cells. Exp 
Gerontol 43, 1114-1122. 
Liang, F. Q., and Godley, B. F. (2003). Oxidative stress-induced mitochondrial DNA 
damage in human retinal pigment epithelial cells: a possible mechanism for RPE 
aging and age-related macular degeneration. Exp. Eye Res. 76, 397–403. 
Lindmo, K., Stenmark, H. (2006). Regulation of membrane traffic by phosphoinositide 3-
kinases. J Cell Sci 119, 605–14.  
Lou, Z., Ren, T., Peng, X. et al. (2013). Bortezomib induces apoptosis and autophagy in 
osteosarcoma cells through mitogen-activated protein kinase pathway in vitro. J Int 
Med Res. 41, 1505–1519. 
Louie, J. L., Kapphahn, R. J., Ferrington, D. A. (2002). Proteasome function and protein 
oxidation in the aged retina. Exp. Eye Res. 75, 271–284. 
Löw, P., Varga, A., Pircs, K. et al. (2013). Impaired proteasomal degradation enhances 
autophagy via hypoxia signaling in Drosophila. BMC Cell Biology, 14, 29.  
86 
 
Maeda, H., Ogata, N., Yi, X., Takeuchi, M., Ohkuma, H., Uyama, M., (1998). Apoptosis 
of photoreceptor cells in ornithine-induced retinopathy. Graefes Arch. Clin. Exp. 
Ophthalmol. 236(3), 207–212. 
Marino, G., Madeo, F., Kroemer, G. (2010). Autophagy for tissue homeostasis and 
neuroprotection. Curr Opin Cell Biol. 23(2), 198-206-  
Marino, G., Ugalde, A. P., Salvador-Montoliu, N., Varela, I., Quiros, P. M., Cadinanos, 
J., van der Pluijm, I., Freije, J. M., and Lopez-Otin, C. (2008). Premature aging in 
mice activates a systemic metabolic response involving autophagy induction. Hum. 
Mol. Genet. 17(14), 2196–2211.  
Martin, D.M., Yee, D., and Feldman, E.L. (1992). Gene expression of the insulin-like 
growth factors and their receptors in cultured human retinal pigment epithelial cells. 
Brain Res Mol Brain Res 12, 181–186. 
Mathivanan, S., Lim, J. W., Tauro, B. J., Ji, H., Moritz, R. L., Simpson, R. J. (2010).  
Proteomics analysis of A33 immunoaffinity-purified exosomes released from the 
human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. 
Mol Cell Proteomics.9(2), 197-208. 
Matsumoto, M., Yoshimura, N., Honda, Y., (1994). Increased production of transforming 
growth factor-beta 2 from cultured human retinal pigment epithelial cells by 
photocoagulation. Invest. Ophthalmol. Vis. Sci. 35 (13), 4245–4252. 
Mauger, C., Del-Favero, J., Ceuterick, C. et al. (1999). Identification and localization of 
ataxin-7 in brain and retina of a patient with cerebellar ataxia type II using anti-
peptide antibody. Brain Res. Mol. Brain Res. 74(1–2), 35–43. 
Maxwell, P.H., Wiesener, M.S, Chang, G.W. et al. (1999). The tumour suppressor protein 
VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 
399, 271-275.  
McGeer, E. G., Klegeris, A. McGeer, P. L. (2005). Inflammation, the complement system 
and the diseases of aging. Neurobiol. Aging 26(1), 94–97. 
Miceli, M., Liles, M., Newsome, D. et al. (1994). Evaluation of oxidative processes in 
human pigment epithelial cells associated with retinal outer segment phagocytosis. 
Exp. Cell Res. 214, 242–249. 
Mitter, S.K., Rao, H.V., Qi, X., Cai, J., Sugrue, A., Dunn, W.A., Jr., Grant, M.B., 
Boulton, M.E. (2012). Autophagy in the retina: a potential role in age-related 
macular degeneration. Adv. Exp. Med. Biol. 723, 83–90. 
Mizushima, N., Yamamoto, A., Hatano, M., et al. (2001). Dissection of autophagosome 
formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol 152, 657–
68. 87. 
Mizushima, N., Yoshimori, T. (2007). How to interpret LC3 immunoblotting. Autophagy 
306, 542–545.  
Mullins, R.F., Russell, S.R., Anderson, D.H., Hageman, G.S., (2000). Drusen associated 
with aging and age-related macular degeneration contain proteins common to 
extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and 
dense deposit disease. FASEB J. 14, 835–846. 
87 
 
Naash, M., Al-Ubaidi, M.R., Anderson, R.E. (1997). Light exposure induces ubiquitin 
conjugation and degradation activities in the rat retina. Invest. Ophthalmol. Vis. Sci. 
38(11), 2344–2354. 
Naash, M., Izbicka, E., Anderson, R.E. (1991). Rat retina has an active and stable 
ubiquitin–protein conjugating system. J. Neurosci. Res. 30(2), 433–441.  
Nakai, A., Yamaguchi, O., Takeda, T. et al. (2007). The role of autophagy in 
cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 
13, 619–624. 
Naujokat, C., Sezer, O., Zinke, H. et al. (2000) Proteasome inhibitors induce caspase-
dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature 
leukemic cells. Eur J Haematol 65, 221-236. 
Nozaki, M., Raisler, B.J., Sakurai, E. et al. (2006). Drusen complement components C3a 
and C5a promote choroidal neovascularization. PNAS 103(7), 2328–2333.  
Ohno, S., Ishikawa, A., Kuroda, M. (2012). Roles of exosomes and microvesicles in 
disease pathogenesis Advanced Drug Delivery Review 65(3), 398-401. 
Olinski, R., Siomek, A., Rozalski, R., Gackowski, D., Foksinski, M., Guz, J., Dziaman, 
T., Szpila, A., Tudek, B. (2007). Oxidative damage to DNA and antioxidant status 
in aging and age-related diseases. Acta Biochimica Polonica.54(1), 11–26. 
Olive, M., van Leeuwen, F. W., Janue, A. (2008). Expression of mutant ubiquitin 
(UBBþ1) and p62 in myotilinopathies and desminopathies. Neuropathol. Appl. 
Neurobiol. 34, 76–87. 
Owen, C., Jarrar, Z., Wormald, R. et al. (2012). The estimated prevalence and incidence 
of late stage age related macular degeneration in the UK. Br J Ophthalmol e301109 
Özkaynak, E., Finley, D., Varshavsky, A. (1984). The yeast ubiquitin gene: head-to-tail 
repeats encoding a polyubiquitin precursor protein. Nature, 312(12), 663-666. 
Pandey, U.B., Nie, Z., Batlevi, Y. et al. (2007). HDAC6 rescues neurodegeneration and 
provides an essential link between autophagy and the UPS. Nature 447, 859–863.  
Pankiv, S., Clausen, T. H., Lamark, T. et al. (2007). p62/SQSTM1 binds directly to 
Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by 
autophagy. The Journal of Biological Chemistry, 282(33), 24131–45.  
Parier, V., Soubrane, G. (2008) Age-related macular degeneration. La Revue de médecine 
interne. 29, 215–223. 
Patel, A.S., Lin, L., Geyer, A., Haspel, J. A., Hyeok An, C., Cao, J., Rosas, I.O., Morse, 
D. (2012). Autophagy in idiopathic pulmonary fibrosis. PLoS ONE 7(7): e41394. 
Penfold, P.L., Madigan, M.C., Gillies, M.C., Provis, J.M. (2001). Immunological and 
etiological aspects of macular degeneration. Prog Retin Eye Res 20, 385-414.  
Peracchio, C., Alabiso, O., Valente, G., Isidoro, C. (2012). Involvement of autophagy in 
ovarian cancer: a working hypothesis. J Ovarian Res 5(22).  
Polson, H.E., de Lartigue, J., Rigden, D.J. et al. (2010). Mammalian Atg18 (WIPI2) 
localizes to omegasome-anchored phago phores and positively regulates LC3 
lipidation. Autophagy 6, 506–22.  
Philp, N. J. (2003). Polarized Expression of Monocarboxylate Transporters in Human 
Retinal Pigment Epithelium and ARPE-19 Cells. Investigative Ophthalmology & 
Visual Science, 44(4), 1716–1721.  
88 
 
Qin, S. (2007). Oxidative Damage of Retinal Pigment Epithelial Cells and Age-Related 
Macular Degeneration. Drug development research. 68, 213–225. 
Qureshi, N., Vogel, S. N., Van Way, C., Papasian, C. J., Qureshi, A. A., Morrison, D. C. 
(2005). The proteasome: a central regulator of inflammation and macrophage 
function. Immunol. Res. 31, 243–260. 
Rapino, C., Bianchi, G., Di Giulio, C. et al. (2005). HIF-1alpha cytoplasmic accumu-
lation is associated with cell death in old rat cerebral cortex exposed to intermittent 
hypoxia. Aging Cell 4, 177–185. 
Rattner, A., Nathans, J. (2006). Macular degeneration: recent advances and therapeutic 
opportunities. Nature Reviews. Neuroscience, 7(11), 860–72.  
Ravikumar, B., Duden, R., Rubinsztein, D.C. (2002) Aggregate-prone proteins with 
polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol 
Genet 11, 1107-17. 
Ravikumar, B., Moreau, K., Jahreiss, L. et al. (2010). Plasma membrane contributes to 
the formation of pre-autophago- somal structures. Nat Cell Biol 12, 747–57.  
Ravikumar, B., Vacher, C., Berger, Z. et al. (2004). Inhibition of mTOR induces 
autophagy and reduces toxicity of polyglutamine expansions in fly and mouse 
models of Huntington disease. Nat Genet 36, 585-95. 
Reme, C. E., Young, R. W. (1977). The effects of hibernation on cone visual cells in the 
ground squirrel. Investigative ophthalmology & visual science 16, 815-840. 
Sahani, M. H., Itakura, E., Mizushima, N. (2014). Expression of the autophagy substrate 
SQSTM1/p62 is restored during prolonged starvation depending on transcriptional 
upregulation and autophagy-derived amino acids. Autophagy 10(3), 431–41.  
Salceda, S., Caro, J. (1997). Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is 
rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. 
Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272, 
22642-7.  
Salminen, A., & Kaarniranta, K. (2009). Regulation of the aging process by autophagy. 
Trends in Molecular Medicine, 15(5), 217–24.  
Sarbassov, D.D., Ali, S.M., Kim, D.H. et al. (2004). Rictor, a novel bin- ding partner of 
mTOR, defines a rapamycin-insensitive and raptor-independent pathway that 
regulates the cytoskeleton. Curr Biol. 14, 1296–1302. 
Schlingemann, R.O., (2004). Role of growth factors and the wound healing re- sponse in 
age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 242, 91-
101. 
Seibenhener, M.L., Babu, J.R., Geetha, T. et al. (2004) Sequestosome 1/p62 is a 
polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. 
Mol Cell Biol 24, 8055-68. 
Selimovic, D., Porzig, B.B., El-Khattouti, A. et al. (2013). Bortezomib/ proteasome 
inhibitor triggers both apoptosis and auto- phagy-dependent pathways in melanoma 
cells. Cell Signal. 25, 308–318. 
Shang, F., Nowell, T. R., Jr., Taylor, A. (2001). Removal of oxidatively damaged 
proteins from lens cells by the ubiquitin-proteasome pathway. Exp. Eye Res. 73, 
229–238. 
89 
 
Shang, F., Taylor, A. (2004). Function of the ubiquitin proteolytic pathway in the eye.  
Experimental Eye Research, 78(1), 1-14. 
Shang, F., Taylor, A. (2012). Roles for the ubiquitin-proteasome pathway in protein 
quality control and signaling in the retina: implications in the pathogenesis of age-
related macular degeneration. Molecular Aspects of Medicine, 33(4), 446–66.  
Sheaff, R., Singer, J., Swanger, J. (2000). Proteasomal Turnover of p21 Cip1 Does Not 
Require p21 Cip1 Ubiquitination. Molecular Cell 5, 403–410.  
Sparrow, J.R., Boulton, M. (2005): RPE lipo- fuscin and its role in retinal pathobiology. 
Exp Eye Res 80, 595–606.  
Sternfeld, M.D., Robertson, J.E., Shipley, G.D., Tsai, J., Rosenbaum, J.T., (1989). 
Cultured human retinal pigment epithelial cells express basic fibroblast growth 
factor and its receptor. Curr. Eye Res. 8 (10), 1029–1037.  
Strauss, O. (2005) The Retinal Pigment Epithelium in Visual Function. Physiol Rev.85, 
845-881. 
Streilein, J.W., Ma, N., Wenkel, H., Ng, T.F., Zamiri, P., (2002). Immunobiology and 
privilege of neuronal retina and pigment epithelium transplants. Vision Res. 42(4), 
487–495. 
Swaroop, A., Branham, K.E., Chen, W., Abecasis, G. (2007). Genetc susceptibility to 
age-related macular degeneration: a paradigm for dissecting complex disease traits. 
Human Molecular Genetics 16(2), 174-182.  
Tan, J.M., Wong, E., Dawson, V.L., Dawson, T.M., Kah-Leong, L. (2008). Lysine 63-
linked polyubiquitin potentially partners with p62 to promote the clearance of 
protein inclusions by autophagy. Autophagy 4(2), 251-253. (Article Addendum) 
Tanihara, H., Yoshida, M., Matsumoto, M., Yoshimura, N., (1993). Identification of 
transforming growth factor-beta expressed in cultured human retinal pigment 
epithelial cells. Invest. Ophthalmol. Vis. Sci. 34 (2), 413–419. 
Tasdemir, E., Galluzzi, L., Maiuri, M.C. et al. (2008). Methods for assessing autophagy 
and autophagic cell death. Methods Mol Biol 445, 29–76. 
Teicher, B.A., Ara, G., Herbst, R. et al. (1999). The proteasome inhibitor PS-341 in 
cancer therapy. Clin Cancer Res. 5, 2638–2645. 
Tezel, T.H., Del Priore, L.V., Kaplan, H.J., (2004). Reengineering of aged Bruch’s 
membrane to enhance retinal pigment epithelium repopulation. Invest. Ophthalmol. 
Vis. Sci. 45(9), 3337–3348. 
Thompson, D., McHenry, C., Li, Y. et al. (2002). Retinal Dystrophy Due to Paternal 
Isodisomy for Chromosome 1 or Chromosome 2, with Homoallelism for Mutations 
in RPE65 or MERTK, respectively. AJHG Cell Press 70(1), 224-229.  
Thornton, J., Edwards, R., Mitchell, P., Harrison, R.A., Buchan, I., et al. (2005). Smoking 
and age-related macular degeneration: a review of association. Eye 19, 935–944. 
Uchiki, T., Weikel, K.A., Jiao, W. et al. (2012) Glycation-altered proteolysis as a 
pathobiological mechanism that links dietary glycemic index, aging, and age-
related disease (in nondiabetics). Aging Cell 11, 1–13. 
Uetama, T., Ohno-Matsui, K., Nakahama, K. et al. (2003). Phenotypic change regulates 
monocyte chemoattractant protein-1 (MCP-1) gene expression in human retinal 
pigment epithelial cells. J. Cell. Physiol. 197(1), 77–85. 
90 
 
Ushio-Fukai, M., Nakamura, Y. (2008). Reactive oxygen species and angiogenesis: 
NADPH oxidase as target for cancer therapy. Cancer Lett. 266, 37–52. 
Viiri, J., Amadio, M., Marchesi, N. et al. (2013). Autophagy activation clears 
ELAVL1/HuR-mediated accumulation of SQSTM1/p62 during proteasomal 
inhibition in human retinal pigment epithelial cells. PloS One, 8(7), e69563.  
Viiri, J., Hyttinen, J. M. T., Ryhänen, T. et al. (2010). P62/Sequestosome 1 As a 
Regulator of Proteasome Inhibitor-Induced Autophagy in Human Retinal Pigment 
Epithelial Cells. Molecular Vision, 16(7), 1399–414.  
Vingerling, J.R., Klaver, C.C., Hofman, A., de Jong, P.T., (1995). Epidemiology of age-
related maculopathy. Epidemiol. Rev. 17(2), 347–360. 
Vittal Rao H, Cai J, Afzal A. et al. (2009). A decline in autophagic efficiency is 
associated with AMD and chronic exposure to oxidative stress. Invest Ophthalmol 
Vis Sci 2009(50).  
Wang, A., Lukas, T., Yuan, M., Du, N. (2009). Autophagy, exosomes and drusen 
formation in age-related macular degeneration. Autophagy (5), 563–564.  
Wang, A. L., Lukas, T. J., Yuan, M. et al. (2009a). Autophagy and exosomes in the aged 
retinal pigment epithelium: possible relevance to drusen formation and age-related 
macular degeneration. PloS One, 4(1), e4160.  
Wang, A. L., Lukas, T.J., Yuan, M. et al. (2009b) Changes in Retinal Pigment Epithelium 
Related to Cigarette Smoke: Possible Relevance to Smoking as a Risk Factor for 
Age-Related Macular Degeneration. PLoS ONE 4(4): e5304. 
Wangsa-Wirawan, N.D., Linsenmeier, R.A. (2003). Retinal oxygen. Fundamental and 
clinical aspects. Arch. Ophthalmol. 121, 547–557.  
Weikel, K.A., Fitzgerald, P., Shang, F., Caceres, M.A., Bian, Q., Handa, J.T., Stitt, A.W., 
Taylor, A. (2011). Natural history of age-related retinal lesions that precede AMD 
in mice fed high or low glycemic index diets. Invest. Ophthalmol. Vis. Sci.53(2), 
622-632. 
Wilson, M. I., Gill, D. J., Perisic, O. et al. (2003). PB1 domain-mediated hetero-
dimerization in NADPH oxidase and signaling complexes of atypical protein kinase 
C with Par6 and p62. Mol. Cell 12, 39–50. 
Winkler, B.S., Boulton, M.E., Gottsch, J.D., Sternberg, P. (1999). Oxidative damage and 
age-related macular degeneration. Mol Vis 5(32). 
Wojcik, S. (2013). Crosstalk between autophagy and proteasome protein degradation 
systems: possible implications for cancer therapy. Folia Histochemica et 
Cytobiologica 51(4), 249–64.  
Wong, T.Y., Liew, G., Mitchell, P. (2007). Clinical update: new treatments for age-
related macular degeneration. Lancet 370, 204–6. 
Wu, W.K., Cho, C.H., Lee, C.W. et al. (2010). Proteasome inhibition: a new therapeutic 
strategy to cancer treatment. Cancer Lett. 293, 15–22. 
Yamamoto, A., Tagawa, Y., Yoshimori, T. (1998). Bafilomycin A1 prevents maturation 
of autophagic vacuoles by inhibiting fusion between autophagosomes and 
lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct. Funct. 23, 33–42. 
91 
 
Yang, Z., Tong, Z., Chen, Y., Zeng, J., Lu, F., et al. (2010) Genetic and Functional 
Dissection of HTRA1 and LOC387715 in Age-Related Macular Degeneration. 
PLoS Genet 6(2): e1000836.  
Yoshida, T., Fukatsu, R., Tsuzuki, K. et al (1997). Amyloid precursor protein, A beta and 
amyloid-associated proteins involved in chloroquine retinopathy in rats–
immunopathological studies. Brain Res. 764(1–2), 283–288. 
Young, R.W. (1967). The renewal of photoreceptor cell outer segments. J Cell Biol.  
33(1):61-72. 
Yuan, G., Nanduri, J., Khan, S. et al. (2008). Induction of HIF- 1alpha expression by 
intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl 
hydroxylases, and mTOR. J. Cell. Physiol. 217, 674–685. 
Zhang, X., Li, W., Wang, C. et al. (2014). Inhibition of autophagy enhances apoptosis 
induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 
cells. Mol Cell Biochem 385, 265–275. 
Zhang, X., Zhou, J., Fernandes, A.F., Sparrow, J.R., Pereira, P., Taylor, A., Shang, F. 
(2008). The proteasome: a target of oxidative damage in cultured human retina 
pigment epithelial cells. Invest Ophthalmol Vis Sci. 49(8), 3622-3630. 
Zhao, J., Brault, J.J., Schild, A. et al. (2007). FoxO3 coordinately activates protein 
degradation by the autophagic/lysosomal and proteasomal pathways in atrophying 
muscle cells. Cell Metabolism 6(6), 472–483. 
Zhou, J., Cai, B., Jang, Y.P., Pachydaki, S., Schmidt, A.M., Sparrow, J.R. (2005). 
Mechanisms for the induction of HNE- MDA- and AGE-adducts, RAGE and 
VEGF in retinal pigment epithelial cells. Exp. Eye Res. 80, 567-580. 
Zhou, J., Jang, Y.P., Kim, S.R., Sparrow, J.R. (2006) Complement activation by 
photooxidation products of A2E, a lipofuscin constituent of the retinal pigment 
epithelium. Proc Natl Acad Sci USA 103, 16182-16187. 
 
